View Filing Data

Document and Entity Information	3 Months Ended
Document and Entity Information	Nov. 30, 2012
Document and Entity Information [Abstract]
Document Type	S-1
Amendment Flag	false
Document Period End Date	Feb. 01, 2013
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Entity Filer Category	Smaller Reporting Company

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Nov. 30, 2012	Aug. 31, 2012	Aug. 31, 2011
CURRENT ASSETS:
Cash and cash equivalents	$ 5,531,075	$ 4,430,740	$ 1,513,365
Short term deposits (note 2)		454,381	1,801,400
Marketable securities (note 3)	1,064,808	200,311	384,565
Restricted cash (note 1n)	16,000	16,000	16,000
Accounts receivable - other (note 4)	75,950	87,691	542,891
Prepaid expenses	18,804	2,307	1,670
Related parties (note 16)	1,719	404
Grants receivable from the chief scientist	99,533	84,642	24,191
T o t a l current assets	6,807,889	5,276,476	4,284,082
LONG TERM DEPOSITS AND INVESTMENT (note 9b)	9,316	8,867	10,186
AMOUNTS FUNDED IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT (note 8)	5,165	4,740	14,293
PROPERTY AND EQUIPMENT, net (note 6)	2,497	4,768	17,376
T o t a l assets	6,824,867	5,294,851	4,325,937
CURRENT LIABILITIES:
Accounts payable and accrued expenses (note 12)	287,302	597,173	375,538
Related parties (note 16)			18,502
Account payable with former shareholder	47,252	47,252	47,252
T o t a l current liabilities	334,554	644,425	441,292
LONG TERM LIABILITIES:
Warrants (notes 7)		637,182
Employee rights upon retirement (note 8)	12,174	6,959	22,675
Provision for uncertain tax position (note 15e)	228,272	228,272	138,054
Total long term liabilities	240,446	872,413	160,729
COMMITMENTS (note 9)
STOCKHOLDERS' EQUITY:
Common stock	86,504	80,075	70,104
Accumulated other comprehensive income	235,868
Additional paid-in capital	24,778,025	21,568,192	18,201,111
Deficit accumulated during the development stage	(18,850,530)	(17,870,254)	(14,547,299)
T o t a l stockholders' equity	6,249,867	3,778,013	3,723,916
T o t a l liabilities and stockholders' equity	$ 6,824,867	$ 5,294,851	$ 4,325,937

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	Nov. 30, 2012	Aug. 31, 2012	Aug. 31, 2011
CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]
Common stock, par value per share	$ 0.012	$ 0.012	$ 0.012
Common stock, shares authorized	16,666,667	16,666,667	16,666,667
Common stock, shares issued	7,209,652	6,673,829	5,842,803
Common stock, shares outstanding	7,209,652	6,673,829	5,842,803

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		12 Months Ended		125 Months Ended	128 Months Ended
	Nov. 30, 2012	Nov. 30, 2011	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012	Nov. 30, 2012
CONDENSED CONSOLIDATED STATEMENTS OF OPERATION [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES, NET (note 13)	$ 392,626	$ 184,016	$ 1,680,845	$ 1,159,309	$ 9,532,694	$ 9,925,320
IMPAIRMENT OF INVESTMENT					434,876	434,876
GENERAL AND ADMINISTRATIVE EXPENSES (note 14)	339,213	281,901	1,203,164	1,275,960	8,161,547	8,500,760
OPERATING LOSS	731,839	465,917	2,884,009	2,435,269	18,129,117	18,860,956
FINANCIAL INCOME	(72,244)	(6,954)	(13,126)	(33,232)	(207,158)	(279,402)
GAIN ON SALE OF INVESTMENT				(1,033,004)	(1,033,004)	(1,033,004)
Impairment of available for sales security			184,254	197,412	381,666	381,666
FINANCIAL EXPENSE	299,158	19,556	199,123	18,780	380,380	679,538
LOSS BEFORE TAXES ON INCOME	958,753	478,519	3,254,260	1,585,225	17,651,001	18,609,754
TAXES ON INCOME (note 15)			90,218	(23,980)	240,776	240,776
NET LOSS FOR THE PERIOD	958,753	478,519	$ 3,344,478	$ 1,561,245	$ 17,891,777	18,850,530
OTHER COMPREHENSIVE INCOME, NET OF TAX
SUBSEQUENT INCREASE IN THE FAIR VALUE OF AVAILABLE FOR SALE SECURITIES PREVIOUSLY WRITTEN DOWN AS IMPAIRED	117,347	4,205				117,347
UNREALIZED GAIN ON AVAILABLE FOR SALE SECURITIES	118,521					118,521
TOTAL OTHER COMPREHENSIVE INCOME	235,868	4,205				235,868
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 722,885	$ 474,314				$ 18,614,662
BASIC AND DILUTED LOSS PER COMMON SHARE	$ 0.14	$ 0.08	$ (0.57)	$ (0.29)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON SHARE	6,826,896	5,842,803	5,884,595	5,417,278

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional paid-in capital [Member]	Deficit accumulated during the development stage [Member]
BALANCE at Apr. 11, 2002	$ 53,700	$ 34,828	$ 18,872
BALANCE, shares at Apr. 11, 2002		2,902,350
SHARES CANCELLED		$ 19,800	(19,800)
SHARES CANCELLED, shares		(1,650,000)
SHARES ISSUED FOR INVESTMENT IN ISTI-NJ	434,876	$ 1,144	433,732
SHARES ISSUED FOR INVESTMENT IN ISTI-NJ, shares		95,368
SHARES ISSUED FOR OFFERING COSTS		$ 1,753	(1,753)
SHARES ISSUED FOR OFFERING COSTS, shares		146,079
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	2,122,981	$ 27,181	2,095,800
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares		2,265,514
SHARES ISSUED FOR SERVICES RENDERED	98,750	$ 125	98,625
SHARES ISSUED FOR SERVICES RENDERED, shares		10,417
CONTRIBUTIONS TO PAID IN CAPITAL	18,991		18,991
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	1,968,547		1,968,547
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	177,782		177,782
DISCOUNT ON CONVERTIBLE NOTE RELATED TO BENEFICIAL CONVERSION FEATURE	108,000		108,000
OTHER COMPREHENSIVE LOSS	(16)			(16)
IMPUTED INTEREST	8,437		8,437
NET LOSS	(4,478,917)			(4,478,917)
BALANCE at Aug. 31, 2007	513,131	$ 44,231	4,946,833	(4,478,933)
BALANCE, shares at Aug. 31, 2007		3,769,728
BALANCE at Apr. 11, 2002	53,700	$ 34,828	18,872
BALANCE, shares at Apr. 11, 2002		2,902,350
NET LOSS	(17,891,777)
BALANCE at Aug. 31, 2012	$ 3,778,013	$ 80,075
BALANCE, shares at Aug. 31, 2012	6,673,829	6,673,829
BALANCE at Apr. 11, 2002	$ 53,700	$ 34,828	18,872
BALANCE, shares at Apr. 11, 2002		2,902,350
OTHER COMPREHENSIVE LOSS	(18,614,662)
NET LOSS	(18,850,530)
BALANCE at Nov. 30, 2012	$ 6,249,867	$ 86,504	24,778,025	(18,850,530)
BALANCE, shares at Nov. 30, 2012	7,209,652	7,209,652
BALANCE at Aug. 31, 2007	$ 513,131	$ 44,231	4,946,833	(4,478,933)
BALANCE, shares at Aug. 31, 2007		3,769,728
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	5,784,800	$ 10,178	5,774,622
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares		848,288
SHARES ISSUED FOR SERVICES RENDERED	116,110	$ 293	115,817
SHARES ISSUED FOR SERVICES RENDERED, shares		24,419
RECEIPTS ON ACCOUNT OF SHARES AND WARRANTS	6,061		6,061
SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE	275,000	$ 550	274,450
SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE, shares		45,844
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	459,467		459,467
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	203,982		203,982
IMPUTED INTEREST	3,780		3,780
NET LOSS	(2,769,271)			(2,769,271)
BALANCE at Aug. 31, 2008	4,593,060	$ 56,252	11,785,012	(7,248,204)
BALANCE, shares at Aug. 31, 2008		4,688,279
SHARES ISSUED FOR SERVICES RENDERED	152,928	$ 204	152,724
SHARES ISSUED FOR SERVICES RENDERED, shares		17,012
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	436,025		436,025
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	117,174		117,174
IMPUTED INTEREST	3,780		3,780
NET LOSS	(2,760,474)
BALANCE at Aug. 31, 2009	2,746,192	$ 56,456	12,698,414	(10,008,678)
BALANCE, shares at Aug. 31, 2009		4,705,291
SHARES ISSUED FOR SERVICES RENDERED	249,850	$ 1,109	248,741
SHARES ISSUED FOR SERVICES RENDERED, shares		92,416
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	690,882		690,882
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	116,944		116,944
IMPUTED INTEREST	3,780		3,780
NET LOSS	(2,977,376)			(2,977,376)
BALANCE at Aug. 31, 2010	830,272	$ 57,565	13,758,761	(12,986,054)
BALANCE, shares at Aug. 31, 2010		4,797,707
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	3,694,212	$ 984,209	3,682,404
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares		11,808,626
SHARES ISSUED FOR SERVICES RENDERED	227,569	$ 731	226,838
SHARES ISSUED FOR SERVICES RENDERED, shares		60,887
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	502,593		502,593
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	26,733		26,733
IMPUTED INTEREST	3,782		3,782
NET LOSS	(1,561,245)
BALANCE at Aug. 31, 2011	$ 3,723,916	$ 70,104	18,201,111	(14,547,299)
BALANCE, shares at Aug. 31, 2011	5,842,803	5,842,803
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	$ 2,851,760	$ 9,622	2,842,138
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares		801,942
SHARES ISSUED FOR SERVICES RENDERED	107,860	$ 349	107,511
SHARES ISSUED FOR SERVICES RENDERED, shares		29,084
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	275,241		275,241
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	117,098		117,098
NET LOSS	(3,344,478)			(3,322,955)
BALANCE at Aug. 31, 2012	$ 3,778,013	$ 80,075
BALANCE, shares at Aug. 31, 2012	6,673,829	6,673,829
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	$ 1,430,092	$ 4,039	1,426,053
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares		336,651
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	190,192		190,192
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	28,016		28,016
OTHER COMPREHENSIVE LOSS	(722,885)
NET LOSS	(958,753)			(958,753)
BALANCE at Nov. 30, 2012	$ 6,249,867	$ 86,504	$ 24,778,025	$ (18,850,530)
BALANCE, shares at Nov. 30, 2012	7,209,652	7,209,652

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended		125 Months Ended	128 Months Ended
	Nov. 30, 2012	Nov. 30, 2011	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012	Nov. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (958,753)	$ (478,519)	$ (3,344,478)	$ (1,561,245)	$ (17,891,777)	$ (18,850,530)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,271	6,042	14,737	28,303	120,844	123,115
Amortization of debt discount					108,000	108,000
Exchange differences on long term deposits	18,782	(21,230)	62,494	(30,791)	31,037	49,819
Stock based compensation	218,208	51,296	271,158	529,326	4,971,287	5,189,495
Common stock issued for services			107,860	227,569	1,155,956	1,155,956
Shares to be issued for services rendered		24,900				24,900
Gain on sale of investment				(1,033,004)	(1,033,004)	(1,033,004)
Impairment of investments					434,876	434,876
Impairment of available-for-sale securities			184,254	197,412	381,666	381,666
Imputed interest				3,782	23,559	23,559
Exchange of warrants	296,982					296,982
Changes in fair value of warrant liabilities	(44,699)		142,704		142,704	98,005
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(20,962)	(49,727)	(31,199)	(36,105)	(160,159)	(181,121)
Restricted cash				8	(16,000)	(16,000)
Accounts payable and accrued expenses	(309,870)	(16,920)	203,133	(17,290)	597,173	287,303
Liability of employee rights upon retirement	5,215	88	(2,489)	22,675	20,186	25,401
Provision for uncertain tax position			90,218	(36,484)	228,272	228,272
Total net cash used in operating activities	(792,826)	(484,070)	(2,301,608)	(1,705,844)	(10,885,380)	(11,073,790)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			(2,129)	(2,180)	(125,612)	(125,612)
Purchase of short term deposits			(475,353)	(1,700,382)	(5,903,735)	(5,903,735)
Proceeds from sale of short term deposits	454,381		1,800,000		5,428,000	5,882,381
Proceeds from sale of investment		450,000	450,000		450,000	450,000
Funds in respect of employee rights upon retirement	(154)	(1,061)	(3,620)	(3,275)	(6,895)	(7,049)
Lease deposits				2,407	(7,509)	(7,509)
Total net cash provided by (used in) investing activities	454,227	448,939	1,768,898	(1,703,430)	(165,751)	(288,476)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants - net of issuance expenses	1,458,436		3,488,942	3,694,212	15,144,635	16,603,071
Receipts on account of shares issuances					6,061	6,061
Proceeds from convertible notes					275,000	275,000
Proceeds from short term note payable					120,000	120,000
Payments of short term note payable					(120,000)	(120,000)
Shareholder advances					66,243	66,243
Net cash provided by financing activities	1,458,436		3,488,942	3,694,212	15,491,939	16,950,375
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(19,502)	17,381	(38,857)	28,789	(10,068)	(29,570)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS			2,917,375	313,727	4,430,740
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	4,430,740	1,513,365	1,513,365
CASH AND CASH EQUIVALENTS AT END OF PERIOD	5,531,075		$ 4,430,740	1,513,365	4,430,740	5,531,075
Material non cash investing and financing activities:
Discount on convertible note related to beneficial conversion feature					108,000	108,000
Shares and warrants issued for offering costs				$ 76,026	77,779	77,779
Contribution to paid in capital					$ 18,991	18,991
Exchange of warrants	917,809					917,809
Shares and warrants issued for marketable securities	$ 628,630					$ 628,630

SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

12 Months Ended

Nov. 30, 2012

Aug. 31, 2012

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General:

Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd ("Hadasit") (the "First Agreement") to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, see also note 2a.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

The Company has been in the development stage since its formation and has not yet generated any revenues from its operations.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the "Subsidiary"), (together with the Company, "the Group").

The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with the ASC Topic 915 "Development Stage Entities".

Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.

Based on its current cash resources and commitments, and cash received in private offerings in the year ended August 31, 2012 and the three month period ended November 30, 2012 (see note 4b), the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.

Newly issued and recently adopted Accounting Pronouncements

In June 2011, the FASB issued an update to ASC No. 220, "Presentation of Comprehensive Income," which eliminates the option to present other comprehensive income and its components in the statement of shareholders' equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The Company adopted the pronouncement in the first quarter of fiscal year 2013.

Condensed Consolidated Financial Statements Preparation

The condensed consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and on the same basis as the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended August 31, 2012 (the "2012 Form 10-K"). These condensed consolidated financial statements are not audited but in the opinion of management reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair presentation of the results of the periods presented. Certain information and disclosures normally included in annual consolidated financial statements have been omitted in this interim period report pursuant to the rules and regulations of the SEC. Because the condensed consolidated interim financial statements do not include all of the information and disclosures required by U.S. GAAP for annual financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in the 2012 Form 10-K for the year ended August 31, 2012. The results for interim periods are not necessarily indicative of a full fiscal year's results.

Reclassifications

Certain figures in respect of prior years have been reclassified to conform to the current year presentation.

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General

Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd ("Hadasit") (the "First Agreement") to acquire the provisional patent related to orally ingestible insulin pill to be used for the treatment of individuals with diabetes, see also note 9a.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

The Company has been in the development stage since its formation and has not yet generated any revenues from its operations.

The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with the ASC Topic 915 "Development Stage Entities".

Based on its current cash resources and commitments, and cash received in private offerings in 2012 (see notes 10g and 17b), the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.

Accounting principles

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").

Use of estimates in the preparation of financial statements

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates.

As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock based compensation, valuation and impairment of marketable securities and valuation of tax exposure.

Functional currency

The currency of the primary economic environment in which the operations of the Group are conducted is the U.S. dollar ("$" or "dollar").

Most of the group's operating expenses are incurred in dollars. Thus, the functional currency of the Group is the dollar.

Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.

Property and equipment

Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the assets.

Annual rates of depreciation are as follows:

		%
Computers and peripheral equipment		33
Office furniture and equipment		15-33

Leasehold improvements are amortized over the term of the lease which is shorter than the estimated useful life of the improvements.

Income taxes

Deferred taxes

Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.

Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities.

Taxes that would apply in the event of disposal of investments in the subsidiary have not been taken into account in computing deferred taxes, as it is the Company's intention to hold this investment, not to realize it.

Uncertainty in income tax

The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company's policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.

Research and development, net

Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, costs of registered patents materials, supplies, the cost of services provided by outside contractors, including services related to the Company's clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred.

Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company out sources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.

Grants received from the OCS and Bio-Jerusalem are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grants are deducted from the related research and development expenses as the costs are incurred and are presented in R&D expenses, net. See also notes 9j and 9k.

Cash equivalents

The Company considers all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.

Comprehensive loss

The Company has no other comprehensive loss components other than net loss for the fiscal years of 2012 and 2011.

Loss per common share

Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding and shares relating to receipts on account of shares in equity during the period. Outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options and warrants excluded from the calculation of diluted net loss was 1,892,171 for the year ended August 31, 2012 (1,266,700 for the year ended August 31, 2011).

Impairment in value of long-lived assets

The Company reviews long-lived assets, to be held and used, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. In the event the sum of the expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment loss would be recognized, and the assets are written down to their estimated fair values.

Stock based compensation

Equity awards granted to employees are accounted for using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimated forfeitures based on historical experience and anticipated future conditions.

The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.

Warrants issued as part of capital raisings that are classified as a liability

Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) are classified as liabilities in the statement of financial position.

The liability is measured both initially and in subsequent periods in fair value, with changes in fair value charged to finance expenses, net. See note 7.

Fair value measurement:

Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

Level 1:

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:

Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3:

Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of August 31, 2012 the assets or liabilities measured at fair value comprise of:

- available for sale securities (level 1).

- warrants (level 3).

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent.

In order to secure the fulfillment of the Company's obligations under the derivatives agreements, the Company has placed a restricted deposit with the bank in an amount of $16,000.

Available-for-sale securities are reported at fair value with unrealized gains and losses, net of related tax, recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.

The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company's ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses.

Concentration of credit risks

Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, deposit and short term investments which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote.

Newly issued and recently adopted accounting pronouncements:

In May 2011, the Financial Accounting Standard Board ("FASB") issued an accounting update that amends ASC No. 820, "Fair Value Measurement" regarding fair value measurements and disclosure requirements. The amendments are effective during interim and annual periods beginning after December 15, 2011 and are to be applied prospectively. The Company adopted the accounting update beginning in the third quarter of fiscal year 2012. As applicable to the Company, the adoption of the new guidance did not have any material impact on the consolidated financial statements.

In June 2011, the FASB issued an update to ASC No. 220, "Presentation of Comprehensive Income," which eliminates the option to present other comprehensive income and its components in the statement of shareholders' equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The accounting update will be applicable to the Company beginning in the first quarter of fiscal year 2013. The adoption of the new guidance is not expected to have a material impact on the consolidated financial statements.

Reclassifications

Certain figures in respect of prior years have been reclassified to conform to the current year presentation.

SHORT TERM INVESTMENTS

12 Months Ended

Aug. 31, 2012

SHORT TERM INVESTMENTS [Abstract]

SHORT TERM INVESTMENTS

NOTE 2 - SHORT TERM INVESTEMNTS:

Amount represents bank deposits with an original maturity of more than three months but less than one year.

	August 31
	2012			2011
	Annual interest rate	Amount		Annual interest rate	Amount
Dollars deposits	0.85%	$	260,371	0.7-0.86%	$	1,801,400
NIS deposits	1.93-1.97%		194,010			-
		$	454,381		$	1,801,400

MARKETABLE SECURITIES

12 Months Ended

Aug. 31, 2012

MARKETABLE SECURITIES [Abstract]

MARKETABLE SECURITIES

NOTE 3 - MARKETABLE SECURITIES:

Marketable securities consist wholly of equity securities of D.N.A Biomedical Solutions Ltd. which were received in March 2011 as part of the consideration for selling the Company's equity method investee Entera. Those securities are classified as available-for-sale and are recorded at fair value. The D.N.A Shares are listed on the Tel Aviv Stock Exchange ("TASE") and their tradability was restricted for a period of 6 months from the closing date of the transaction according to TASE policy with regards to private placements. Until September 30, 2011, the fair value of the restricted securities was measured based on the quoted prices of the otherwise identical unrestricted securities, adjusted for the effect of the restriction by applying a proper discount. The discount was determined with reference to other similar restricted instruments. Similar securities, with no restriction on tradability, are quoted on an active market. As of the first quarter of 2011, the securities are not restricted and the fair value of the securities is measured based on the quoted prices of the securities on an active market.

Financial assets carried at fair value as of August 31, 2012 and August 31, 2011 are classified in the tables below in one of the three categories described above:

	Level 1		Level 3		Total
Marketable securities:
August 31, 2012	$	200,311		-	$	200,311
August 31, 2011		-	$	384,565	$	384,565

The following table summarizes the activity for those financial assets where fair value measurements are estimated utilizing Level 3 inputs:

	August 31
	2012			2011
Carrying value at the beginning of the period	$	384,565		$	-
Additions - see note 5		-			581,977
Reclassification to level 1		(384,565	)		-
Impairment of available-for-sale securities - financial expenses		-			(197,412	)
Carrying value at the end of the period	$	-		$	384,565

As of August 31, 2012, the carrying amount of cash and cash equivalents, accounts receivables, other current assets and accounts payables and accrued expenses approximates their fair values due to the short-term maturities of these instruments.

The fair value of long-term deposits also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

As to financial liabilities carried at fair value, see note 7.

FAIR VALUE

3 Months Ended

Nov. 30, 2012

FAIR VALUE [Abstract]

FAIR VALUE

NOTE 3 - FAIR VALUE:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of November 30, 2012 the assets or liabilities measured at fair value comprise of available for sale securities (level 1).

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

Available-for-sale securities are reported at fair value with unrealized gains and losses, recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of comprehensive loss as an impairment charge and are included in the consolidated statement of comprehensive loss under impairment of available-for-sale securities.

Marketable securities consist wholly of equity securities of D.N.A Biomedical Solutions Ltd. ("D.N.A"), which were received in March 2011 as part of the consideration for selling the Company's equity method investee Entera, and in October 2012, as an option to purchase ordinary shares of D.N.A with no additional costs in exchange for the Company's common stock (the "D.N.A Option"). Those securities are classified as available-for-sale and are recorded at fair value.

The shares received on March 2011 are traded on the Tel Aviv Stock Exchange ("TASE") and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities in an active market on the measurement date.

The D.N.A shares that will be received upon realizing the D.N.A Option will be restricted for a period of 6 months from realization date according to TASE policy with regards to private placements. The fair value of the D.N.A Option is measured based on the quoted prices of the otherwise identical unrestricted securities, adjusted for the effect of the restriction by applying a proper discount. The discount was determined with reference to other similar restricted instruments. The discount will be decreased over the restriction period. As a result, the fair value of the D.N.A. Option at the closing date and as of November 30, 2012, reflects a discount of 8% on the quoted D.N.A share price, based on similar transactions involving restricted shares of pharmaceutical companies under TASE lock-up rules.

Transfers in and/or out of Level 3 are recognized in the beginning of the reporting period.

Financial assets carried at fair value as of November 30, 2012 and August 31, 2012 are classified in the tables below in one of the three categories described above:

	Level 1		Level 3		Total
Marketable securities:
November 30, 2012	$	317,657	$	747,151	$	1,064,808
August 31, 2012	$	200,311		-	$	200,311

The following table summarizes the activity for those financial assets where fair value measurements are estimated utilizing Level 3 inputs:

	Three months ended
	November, 30
	2012
	Unaudited
Carrying value at the beginning of the period	$	-
Additions		628,630
Changes in fair value		118,521
Carrying value at the end of the period	$	747,151

As to financial liabilities carried at fair value, see note 5.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

+ Details

ACCOUNTS RECEIVABLE

12 Months Ended

Aug. 31, 2012

ACCOUNTS RECEIVABLE [Abstract]

ACCOUNTS RECEIVABLE

NOTE 4 - ACCOUNTS RECEIVABLE:

Composition of accounts receivable , grouped by major classifications, is as follows:

	August 31
	2012		2011

Receivables from D.N.A (see note 5)	$	-	$	450,844
Tax Authorities		53,341		32,406
Other receivables		34,350		59,641
	$	87,691	$	542,891

- Definition

The entire disclosure for claims held for amounts due a company. Examples include trade accounts receivables, notes receivables, loans receivables.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3, 4
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 7
-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 01-6
-Paragraph 13
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph k

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3,4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6965416&loc=d3e5074-111524

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6965416&loc=d3e5066-111524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6965416&loc=d3e5162-111524

+ Details

AGREEMENT WITH D.N.A BIOMEDICAL SOLUTIONS LTD

12 Months Ended

Aug. 31, 2012

AGREEMENTS WITH D.N.A. BIOMEDICAL SOLUTIONS LTD [Abstract]

AGREEMENT WITH D.N.A BIOMEDICAL SOLUTIONS LTD

NOTE 5 - AGREEMENT WITH D.N.A BIOMEDICAL SOLUTIONS LTD

In June 2010, the Subsidiary entered into an agreement with D.N.A, for the establishment of a new company, Entera. According to the JV Agreement, D.N.A invested $600,000, in two stages, in Entera, and Entera was owned in equal parts by the Subsidiary and D.N.A. In consideration for 50% of Entera's shares, the Subsidiary entered into a Patent License Agreement with Entera, according to which, the Subsidiary out-licensed to Entera a technology for the development of oral delivery drugs for certain actions.

Mr. Zeev Bronfeld, who is one of D.N.A 's directors and controlling shareholders, is also an affiliated stockholder of the Company.

The Group has concluded Entera was a variable interest entity (a "VIE"), according to the terms of the JV Agreement until its sale in March 2011, as described below.

On February 22, 2011, the Subsidiary entered into a share purchase agreement with D.N.A for the sale of 47% of Entera's outstanding share capital on an undiluted basis. The closing of that transaction took place on March 31, 2011. As consideration for the Entera shares, the Subsidiary received a promissory note issued by D.N.A in the principal amount of $450,000, with an annual interest rate of 0.45%, which was paid on November 14, 2011, and 8,404,667 ordinary shares of D.N.A (the "D.N.A Shares"), having a fair value of $581,977 as of the closing date of the transaction. The D.N.A Shares are listed on the Tel Aviv Stock Exchange ("TASE") and their tradability was restricted for a period of 6 months from the closing date of the transaction according to TASE policy with regards to private placements.

D.N.A.'s securities are classified as available-for-sale, during 2012 and 2011 the Company recognized an impairment of $184,254 and $197,412, respectively.

In addition, on the closing date, D.N.A participated in the Company's private placement, at same investment terms granted to other investors at that period, for which it received 65,104 shares of our common stock and five-year warrants to purchase 22,787 shares of common stock at an exercise price of $6.00 per share for $250,000.

As part of the transaction, the Subsidiary entered into a patent transfer agreement (that replaced the original license agreement) according to which, the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera's net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. On August 31, 2012, Entera had not yet realized any revenues and did not pay any royalties to the Subsidiary.

Upon the closing, Oramed, Entera and D.N.A terminated the joint venture agreement, as amended, entered into on June 1, 2010 in connection with the formation of Entera.

In 2011, the Subsidiary recognized a gain on sale of investment of $1,033,004 from the transaction, as followed:

Fair value of D.N.A Shares	$	581,977
Receivables from D.N.A		450,000
Re-classification of currency translation adjustments		7,930
	$	1,039,907
Less - net cost of the investment realized		(6,903	)
	$	1,033,004

As a result of the above transaction, the Company no longer has the ability to exert significant influence over Entera and the remaining 3% interest, in the amount of $1,027, is accounted for at a cost method investment.

PROPERTY AND EQUIPMENT, NET

12 Months Ended

Aug. 31, 2012

PROPERTY AND EQUIPMENT, Net [Abstract]

PROPERTY AND EQUIPMENT, Net

NOTE 6 - PROPERTY AND EQUIPMENT, NET:

Composition of property and equipment, grouped by major classifications, is as follows:

	August 31
	2012		2011
Cost:
Leasehold improvements	$	76,029	$	76,029
Office furniture and equipment		19,941		19,941
Computers and peripheral equipment		29,642		27,513
		125,612		123,483
Less - accumulated depreciation and amortization		120,844		106,107
	$	4,768	$	17,376

Depreciation expenses totaled $14,737 and $28,303 in the years ended August 31, 2012 and 2011, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

WARRANTS

3 Months Ended

12 Months Ended

Nov. 30, 2012

Aug. 31, 2012

WARRANTS [Abstract]

WARRANTS

NOTE 5 - WARRANTS

As part of the Company's private placements, warrants were granted to the Leading Investor, as defined in note 4b. 182,292 warrants were granted in January 2011 (the "2011 Warrants"), 112,613 were granted in August 2012 and 16,892 were granted in November 2012 (together, the "Three Warrants"). Each warrant was granted for five years at an initial exercise price of $6.00 per share. The warrants included a full ratchet anti-dilution protection from the second year anniversary date after issuing the warrant, subject to certain limitations and while the warrant was outstanding. In the event the Company was to issue or sell any common stock for a consideration per share lower than the exercise price then in effect, or was to issue or sell any options, warrants or other rights for the purchase or acquisition of such shares at a consideration per share of less than the exercise price then in effect, the warrants were to be amended to (a) reduce the exercise price to an amount equal to the per share consideration payable to the company in such sale or issuance, and (b) the quantity of warrants were to updated, based on certain rules as determined in the Warrants Agreements with the Leading Investor.

As a result of a private placements in August 2012, and pursuant to adjustment terms of the 2011 Warrants, such warrant was amended to: (i) reduce the exercise price from $6.00 to $4.44, (ii) increase the number of shares issuable upon the exercise of the warrant from 182,292 to 246,341.

In addition, as a result of the agreement with D.N.A, as described in note 4c, and pursuant to adjustment terms of the 2011 Warrants, the Company further amended the 2011 Warrants by: (i) reducing the exercise price from $4.44 to $3.7656 and (ii) increasing the number of shares issuable upon the exercise of the 2011 Warrants from 246,341 to 290,459.

On November 29, 2012, the Company and the Leading Investor entered into a letter agreement (the "Agreement") in connection with the Three Warrants. Pursuant to the Agreement, the Company and the Leading Investor agreed to amend the Three Warrants to provide that the anti-dilution protection of each of the Three Warrants shall be removed in its entirety. In addition, as to the Warrants issued in August and November 2012, the parties agreed that the exercise price shall be reduced to $3.7656. On that day, the Company also issued to the Leading Investor a Common Stock Purchase Warrant (the "New Warrant") pursuant to which, the Leading Investor shall have the right to purchase up to 137,311 shares of the common stock of the Company over a period of four years at an exercise price of $7.20 per share. The fair value of the New Warrant on the date of grant, was $145,173, using the following assumptions: dividend yield of 0% and expected term of 4 years; expected volatility of 62.29%; and risk-free interest rate of 0.57%.

The fair value of the warrants was determined by using Monte Carlo type model based on the risk neutral approach. The model takes as an input the estimated future dates when new capital will be raised, and builds a multi-step dynamic model. The first step is to model the risk neutral distribution of the share value on the new issue dates, then for each path to use the Black-Scholes model to estimate the value of the warrants on the last issue date including all the changes in exercise price and quantity along this path. The significant unobservable input used in the fair value measurement is the future expected issue dates. Significant delay in this input would result a higher fair value measurement.

In addition to the New Warrant, Nadav Kidron, the Company's President, Chief Executive Officer and director, in his personal capacity as a shareholder of the Company, undertook and agreed that following the execution and delivery of the Agreement, in the event that an adjustment pursuant to the anti-dilution protection of any of the Three Warrants (had it not been amended by the Agreement thereof) would have been triggered and the number of shares of common stock of the Company that the Leading Investor would have been able to purchase under the Three Warrants would have increased by an aggregate number in excess of 137,311 shares, then the Leading Investor shall have the right to purchase from Mr. Kidron such number of shares of common stock of the Company owned by Mr. Kidron equal to such excess, up to a maximum of 112,690 shares of common stock of the Company (the "Kidron Option"). The foregoing right shall survive until the termination of such Three Warrants. The fair value of the Kidron Option on the date of grant was $168,220, based on the Monte Carlo type model that is described above.

Pursuant to the removal of the anti-dilution protection, the Three Warrants were no longer classified as liabilities. The Company recognized a financial expense in the amount of $296,982.

Financial liabilities carried at fair value as of August 31, 2012, are classified in the tables below in one of the three fair value categories:

	Fair value measurements at reporting date using
	Level 3		Total
Warrants -
August 31, 2012	$	637,182	$	637,182

The following table summarizes the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs:

	Three months ended November 30
	2012
Carrying value at the beginning of the period	$	637,182
Additional warrant liabilities granted		28,344
Changes in fair value of warrant liabilities		(44,699	)
Exchange of warrants		(620,827	)
Carrying value at the end of the period	$	-

NOTE 7 - WARRANTS

As part of the Company's private placements as described in notes 10a and 10f, warrants were granted to an investor who was considered as a leading investor (the "Leading Investor). 182,292 warrants were granted in January 2011 (the "2011 Warrants") and 112,613 were granted in August 2012. Each warrant was granted for five years at an initial exercise price of $6.00 per share. The warrants include anti-dilution protection (the "full ratchet anti-dilution protection"), from the second year anniversary date after issuing the warrant, subject to certain limitations and while the warrant is outstanding. In the event the Company shall issue or sell any common stock for a consideration per share lower than the exercise price then in effect, or shall issue or sell any options, warrants or other rights for the purchase or acquisition of such shares at a consideration per share of less than the exercise price then in effect, the warrants will be amended to (a) reduce the exercise price to an amount equal to the per share consideration payable to the company in such sale or issuance, and (b) the quantity of warrants will be updated, based on certain rules as determined in the Warrants Agreements with the Leading Investor.

As a result of the August 2012 private placements, and pursuant to the adjustment terms of the 2011 Warrants held by the Leading Investor, prior to such private placements, the warrant held by the Leading Investor was amended to: (i) reduce the exercise price from $6.00 to $4.44, (ii) increase the number of shares issuable upon the exercise of the warrant from 182,292 to 246,341, and (iii) delete the limitation which restricted the Leading Investor 's ability from receiving more than 9.9% of the Company's outstanding shares.

As to amendment to the Warrant after August 31, 2012, see also note 17d.

As of August 31, 2011, the Warrants that were granted to this investor during the year ended August 31, 2011 were presented within stockholders' equity. After further review, the Company has determined that these instruments should have been classified as liabilities. Changes in the fair value of these Warrants require adjustments to the amount of the liabilities recorded on the Company's balance sheet, and the corresponding gain or loss is required to be recorded in the Company's statement of operations. The Company assessed the materiality of the correction and concluded that it was immaterial to previously reported annual and interim amounts and that the correction of the error in 2012 is not material to the current year results of operations. Accordingly, the Company corrected this error during the year ended August 31, 2012 and did not restate its consolidated financial statements for the prior years or interim periods impacted.

Financial liabilities carried at fair value as of August 31, 2012 are classified in the tables below in one of the three fair value categories:

	Fair value measurements at reporting date using
	Level 3		Total
Warrants -
August 31, 2012	$	637,182	$	637,182

The following table summarizes the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs:

	August 31
	2012
Carrying value at the beginning of the period		-
Additions	$	494,478
Changes in fair value of warrant liabilities		142,704
Carrying value at the end of the period	$	637,182

As to the change in the terms of the warrants after August 31, 2012, see note 17e.

EMPLOYEES RIGHTS UPON RETIREMENT	12 Months Ended
EMPLOYEES RIGHTS UPON RETIREMENT	Aug. 31, 2012
EMPLOYEE RIGHTS UPON TERMINATION [Abstract]
EMPLOYEE RIGHTS UPON TERMINATION	NOTE 8 - EMPLOYEES RIGHTS UPON RETIREMENT: The Subsidiary is required to make a severance payment upon dismissal of an employee, or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month's salary for each year employed) is recorded on the Subsidiary's balance sheets under "Liability for employee rights upon retirement." The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis. The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Subsidiary's balance sheets under "Funds in respect of employee rights upon retirement." These policies are the Subsidiary's assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended August 31, 2012 and 2011, the Subsidiary deposited $3,620 and $3,275, respectively, with insurance companies in connection with its severance payment obligations. In accordance with the current employment agreements with certain employees, the Subsidiary makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's rights upon retirement. The Subsidiary is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Subsidiary 's balance sheets, as the amounts funded are not under the control and management of the Subsidiary and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the "Contribution Plans"). The amounts of severance pay expenses were $5,615 and $10,241 for the years ended August 31, 2012 and 2011, respectively. $7,089 and $6,966 in the years ended August 31, 2012 and 2011, respectively, were in respect of a Contribution Plan. The Subsidiary expects to contribute approximately $10,155 in the year ending August 31, 2013 to insurance companies in connection with its severance liabilities for its operations for that year, $7,619 of which will be contributed to one or more Contribution Plans.

COMMITMENTS

3 Months Ended

12 Months Ended

Nov. 30, 2012

Aug. 31, 2012

COMMITMENTS [Abstract]

COMMITMENTS

NOTE 2 - COMMITMENTS:

Under the terms of the First Agreement with Hadasit (note 1a above), the Company retained Hadasit to provide consulting and clinical trial services. As remuneration for the services provided under the agreement, Hadasit is entitled to $200,000. The primary researcher for Hadasit is Dr. Miriam Kidron, a director and officer of the Company. The funds paid to Hadasit under the agreement are deposited by Hadasit into a research fund managed by Dr. Kidron. Pursuant to the general policy of Hadasit with respect to its research funds, Dr. Kidron receives from Hadasit a management fee in the rate of 10% of all the funds deposited into this research fund. The total amount paid to Dr. Kidron out of this fund was $10,214.

On January 7, 2009, the Company entered into a second agreement with Hadasit (the "Second Agreement") which confirms that Hadasit has conveyed, transferred and assigned all of its ownership rights in the patents acquired under the First Agreement to the Company, and certain other patents filed by the Company after the First Agreement as a result of the collaboration between the Company and Hadasit.

On July 8, 2009, the Subsidiary entered into a third agreement with Hadasit, Prof. Itamar Raz and Dr. Miriam Kidron the "Third Agreement"), to retain consulting and clinical trial services from Hadasit. According to the Third Agreement, Hadasit was entitled to total consideration of $400,000 to be paid by Oramed. $200,000 of this amount was agreed in the terms of the First Agreement, and the remaining of $200,000 was paid in accordance with the actual progress of the study. The total amount was paid through May 31, 2011.

On September 11, 2011, the Subsidiary entered into a fourth agreement with Hadasit, Dr. Miriam Kidron and Dr. Daniel Schurr (the "Fourth Agreement"), to retain consulting and clinical trial services. According to the Fourth Agreement, Hadasit will be entitled to consideration of $200,000 to be paid by the Company in accordance with the actual progress of the study, none of which was recognized or paid through November 30, 2012.

On March 18, 2012, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 57 months commencing January 1, 2012. The monthly lease payment will be NIS 3,400 in 2012, NIS 4,225 in 2013 and NIS 5,610 from 2014 onwards, and will be linked to the increase in the Israeli consumer price index (as of November 30, 2012, the monthly payment in the Company's functional currency is $892, the future annual lease payments under the agreement will be $12,441 in 2013, $16,215 in 2013 and $17,669 from 2014 onwards). As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments.

On April 21, 2009, the Subsidiary entered into a consulting service agreement with ADRES Advanced Regulatory Services Ltd. ("ADRES") (the "Original Agreement") pursuant to which ADRES will provide consulting services relating to quality assurance and regulatory processes and procedures in order to assist the Subsidiary in submission of a U.S. Investigational New Drug ("IND") according to the U.S. Food and Drug Administration (the "FDA") regulations. In consideration for the services provided under the agreement, ADRES will be entitled to total cash compensation of $211,000, of which the amount of $110,000 was to be paid as a monthly fixed fee of $10,000 each month for 11 months commencing May 2009, and the remaining $101,000 was to be paid based on achievement of certain milestones. $160,000 of the total amount was paid through November 30, 2011, $50,000 of which was paid for completing the first three milestones.

On February 26, 2012, the parties entered into an amendment agreement, according to which the Subsidiary paid the remaining $51,000 of the Original Agreement upon execution of the amendment agreement. In addition, beginning March 1, 2012 and until submission of the IND, the Subsidiary will pay ADRES a monthly fee of approximately $3,600. The Company recognized the $51,000 as an expense during the year ended August 31, 2012.

On July 5, 2010, the Subsidiary of the Company entered into a Manufacturing Supply Agreement (MSA) with Sanofi-Aventis Deutschland GMBH ("sanofi-aventis"). According to the MSA, sanofi-aventis will supply the subsidiary with specified quantities of recombinant human insulin to be used for clinical trials in the USA.

On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the "Consultant") for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8,000, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera Bio Ltd. ("Entera") on February 22, 2011 and an option to purchase up to 20,834 shares of common stock of the Company at an exercise price of $6.00 per share. The option vests in five annual installments commencing February 16, 2012 and expires on February 16, 2021. The initial fair value of the option on the date of grant was $62,185, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 78.65%; risk-free interest rates of 3.62%; and the remaining expected term of 10 years. The fair value of the option as of August 31, 2012 was $54,345, using the following assumptions: dividend yield of 0% and expected term of 8.5 years; expected volatility of 75.41%; and risk-free interest rate of 1.29%. The fair value of the option granted is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

On December 12, 2011, the Subsidiary issued a purchase order to Swiss Caps AG ("Swiss Caps"), according to which, Swiss Caps will manufacture insulin capsules for total consideration of CHF 395,000 (approximately $426,000) of which CHF 340,000 (approximately $367,000) was paid and recognized through November 30, 2012.

On February 15, 2012, the Company entered into an advisory agreement with a third party for a period of one year, pursuant to which such third party will provide investors relations services and will be entitled to a share based compensation as follows: 25,000 shares of common stock of the Company will be issued in six installments over the engagement period, commencing February 15, 2012, and a warrant to purchase 62,500 shares of common stock of the Company at an exercise price of $6.00 per share. The warrant vests in 12 monthly installments commencing February 15, 2012 and expires on February 15, 2017. The initial fair value of the option on the date of grant was $121,304, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.82%; risk-free interest rates of 0.81%; and the remaining expected term of 5 years.

On July 3, 2012, the Company and the third party entered into an amendment to the agreement, according to which the original agreement will be extended until July 3, 2013 (unless terminated earlier by one of the parties), and a new payment schedule was determined for the remainder of the share based compensation until July 3, 2013. The Company records expenses in respect of this warrant during the term of the services.

The fair value of the option as of November 30, 2012, was $105,455, using the following assumptions: dividend yield of 0% and expected term of 4.2 years; expected volatility of 74.64%; and risk-free interest rate of 0.55%. The fair value of the option granted is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

On September 27, 2012, the Subsidiary entered into a Master Services Agreement with Medpace, Inc. ("Medpace"), to retain it as a CRO, for its upcoming Phase 2 clinical trial for an oral insulin capsule, that is expected to start in the first calendar quarter of 2013 in the United States. As consideration for its services, the subsidiary will pay Medpace a total amount of approximately $3,500,000 that will be paid during the term of the engagement and based on achievement of certain milestones, none of which was recognized or paid through November 30, 2012.

Grants from Bio-Jerusalem

The Subsidiary is committed to pay royalties to the Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $65,053. As of November 30, 2012, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.

In the three months period ended November 30, 2012, the Company received $12,320 from the Bio-Jerusalem fund.

Grants from the Office of the Chief Scientist ("OCS")

Under the terms of the Company's funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest at a rate based on LIBOR.

At the time the grants were received, successful development of the related projects was not assured. In case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.

On November 30, 2012, the Subsidiary had not yet realized any revenues from the said project and did not incur any royalty liability. The total amount that was actually received through November 30, 2012 was $1,332,374.

For the three months period ended November 30, 2012, the research and development expenses are presented net of OCS and Bio-Jerusalem fund Grants, in the total amount of $22,378.

NOTE 9 - COMMITMENTS:

On July 8, 2009, the Company entered into a third agreement with Hadasit, Prof. Itamar Raz and Dr. Miriam Kidron ("the Third Agreement"), to retain consulting and clinical trial services from Hadasit. According to the Third Agreement, Hadasit was entitled to total consideration of $400,000 to be paid by Oramed. $200,000 of this amount was agreed in the terms of the First Agreement, and the remaining of $200,000 was paid in accordance with the actual progress of the study. The total amount was paid through May 31, 2011.

On September 11, 2011, the Company entered into a fourth agreement with Hadasit, Dr. Miriam Kidron and Dr. Daniel Schurr (the "Fourth Agreement"), to retain consulting and clinical trial services. According to the Fourth Agreement, Hadasit will be entitled to consideration of $200,000 to be paid by the Company in accordance with the actual progress of the study. None of which was recognized or paid through August 31, 2012.

The Subsidiary has entered into operating lease agreements for vehicles used by its employees for a period of 3 years.

The lease expenses for the years ended August 31, 2012 and 2011 were $29,543 and $37,144, respectively. The future lease payments under the lease agreement are $21,201, $8,237 and $686 for the years ending August 31, 2013, 2014 and 2015, respectively.

As security for its obligation under the lease agreements the Subsidiary deposited $7,840, which are classified as long term deposits.

On March 18, 2012, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 57 months commencing January 1, 2012. The monthly lease payment will be NIS 3,400 in 2012, NIS 4,225 in 2013 and NIS 5,610 from 2014 onwards, and will be linked to the increase in the Israeli consumer price index (as of August 31, 2012, the monthly payment in the Company's functional currency is $844, the future annual lease payments under the agreement will be $11,768 in 2013, $15,338 in 2013 and $16,713 from 2014 onwards).

As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments.

On April 21, 2009, the Subsidiary entered into a consulting service agreement withADRES Advanced Regulatory Services Ltd. ("ADRES") (the "Original Agreement") pursuant to which ADRES will provide consulting services relating to quality assurance and regulatory processes and procedures in order to assist the Subsidiary in submission of a U.S. Investigational New Drug ("IND") according to the U.S. Food and Drug Administration (the "FDA") regulations. In consideration for the services provided under the agreement, ADRES will be entitled to total cash compensation of $211,000, of which the amount of $110,000 will be paid as a monthly fixed fee of $10,000 each month for 11 months commencing May 2009, and the remaining $101,000 will be paid based on achievement of certain milestones. $160,000 of the total amount was paid through November 30, 2011, $50,000 of which was paid for completing the first three milestones.

On February 10, 2010, the Subsidiary entered into an agreement with Vetgenerics Research G. Ziv Ltd, a clinical research organization, to conduct a toxicology trial on its oral insulin capsules. The total cost estimated for the studies is €107,100 ($154,320) of which €89,923 ($129,570) was paid through August 31, 2012. The Company did not recognized any expense during 2012 with respect to said agreement.

On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the "Consultant") for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8,000, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera on February 22, 2011 and an option to purchase up to 20,834 shares of common stock of the Company at an exercise price of $6.00 per share. The option vests in five annual installments commencing February 16, 2012 and expires on February 16, 2021. The initial fair value of the option on the date of grant was $62,185, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 78.65%; risk-free interest rates of 3.62%; and the remaining expected term of 10 years. The fair value of the option as of August 31, 2012 was $54,345, using the following assumptions: dividend yield of 0% and expected term of 8.5 years; expected volatility of 75.41%; and risk-free interest rate of 1.29%. The fair value of the option granted is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

On June 22, 2011, the Subsidiary issued a purchase order to SAFC Pharma for producing one of its oral capsule ingredients in the amount of $600,000. During the year ended August 31, 2012, only a quantity valued at approximately $444,000 was supplied to the Subsidiary, of which $170,000 was paid through August 31, 2012, and the remaining is presented under accounts payable and accrued expenses.

On December 12, 2011, the Subsidiary entered into a Supply Agreement with Swiss Caps AG ("Swiss Caps"), according to which, Swiss Caps will manufacture insulin capsules for total consideration of CHF 395,000 (approximately $411,000) of which CHF 340,000 (approximately $375,000) was paid and recognized through August 31, 2012.

The fair value of the option as of August 31, 2012, was $115,698, using the following assumptions: dividend yield of 0% and expected term of 4.5 years; expected volatility of 75.41%; and risk-free interest rate of 0.52%. The fair value of the option granted is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

Grants from Bio-Jerusalem

The Subsidiary is committed to pay royalties to the Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $52,733. As of August 31, 2012, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.

During the year ended August 31, 2012 no grants were received from Bio-Jerusalem . For the period from inception on April 12, 2002 through August 31, 2012, the research and development expenses are presented net of Bio-Jerusalem grants, in the total amount of $52,733.

Grants from the Chief Scientist Office ("OCS")

On August 31, 2012, the Subsidiary had not yet realized any revenues from the said project and did not incur any royalty liability. The total amount that was actually received through August 31, 2012 was $1,332,374.

For the years ended August 31, 2012, and 2011, and for the period from inception on April 12, 2002 through August 31, 2012, the research and development expenses are presented net of OCS Grants, in the total amount of $372,959, $296,995 and $1,415,557, respectively.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

STOCK HOLDERS' EQUITY

3 Months Ended

12 Months Ended

Nov. 30, 2012

Aug. 31, 2012

STOCK HOLDERS' EQUITY [Abstract]

STOCK HOLDERS' EQUITY

NOTE 4 - STOCK HOLDERS' EQUITY:

In September 2012, the Company issued 5,652 shares of its common stock and 2,826 common stock purchase warrant to an investor, with whom the Company entered into Securities Purchase Agreement in August 2012.

Between September and November 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 329,832 units at a purchase price of $4.44 per unit for total consideration of $1,464,425. Each unit consisted of one share of the Company's common stock and one common stock purchase warrant. Each warrant entitles the holder to purchase 0.50 a share of common stock exercisable for five years at an exercise price of $6.00 per share. The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. In addition, one of the investors who was previously considered as a leading investor (the "Leading Investor") , who purchased 405,405 of the units, was granted the right to maintain its percentage of the shares of the Company's common stock outstanding by purchasing more shares whenever the Company proposes to issue certain additional shares to other investors. Such right only exists so long as such investor holds at least 5% of the Company's outstanding common stock. In addition, such investor's warrants contained anti-dilution protection (the "full ratchet anti-dilution protection") and cashless exercise provisions not contained in the other investors' warrants. The other terms of the Leading Investor's Securities Purchase Agreement were substantially the same as those granted to him in 2011 for his first investment. See also note 5.

As finder's fee, in connection with the securities purchase agreements, the Company paid cash consideration of $5,385 and might be required to pay additional $7,500, as well as issued 1,127 shares of the Company's common stock and 564 common stock purchase warrant for another individual. The Company will also issue 12,745 shares of the Company's common stock and 6,373 common stock purchase warrant to a director as finder's fee with respect to the Securities Purchase Agreements described above and to Securities Purchase Agreements to which the Company had entered into in August 2012.

On October 30, 2012, the Company entered into a Securities Purchase Agreement with D.N.A, according to which, the Company issued on that day to D.N.A 199,172 shares of its common stock, in consideration for the option to purchase up to 21,637,611 ordinary shares of D.N.A, valued at approximately $628,630 at the day of the transaction. D.N.A has filed an application for the approval of the TASE to list the ordinary shares of D.N.A issuable upon exercise of the D.N.A Option. Mr. Zeev Bronfeld, a controlling shareholder of D.N.A, beneficially owned 7.1% of the Company's outstanding common stock prior to the transaction. As a result of the -holding of Mr. Bronfeld, the Israeli Securities Authority ("ISA") informed D.N.A that in its opinion the procedure of approving the transaction by D.N.A was not in accordance with the applicable law. The Company, based on a legal opinion it has received from counsel, is in the opinion that the procedure was in order, based on precedents and their experience with similar cases.

Following the exercise of the D.N.A Option, the Company will hold approximately 14.5% of D.N.A's outstanding ordinary shares, which includes the 8,404,667 D.N.A shares that were issued to the Company in March 2011.

NOTE 10 - STOCK HOLDERS' EQUITY:

The Company's shares are traded on the Over-The-Counter Bulletin Board.

The following are capital stock transactions that took place during the years ended August 31, 2012 and 2011:

Between November 2010 and February 2011, the Company entered into Securities Purchase Agreements with a few accredited investors for the sale of 808,956 units at a purchase price of $3.84 per unit for total consideration of $3,106,000. Each unit consisted of one share of the Company's common stock and one common stock purchase warrant. Each warrant entitles the holder to purchase 0.35 a share of common stock exercisable for five years at an exercise price of $6.00 per share. For finder's fee with respect to these Securities Purchase Agreements, see note 11c..

As to the warrants purchased by the Leading Investor - see note 7.

On March 31, 2011, the Company consummated a transaction with D.N.A for the sale of 65,104 shares of common stock and warrants to purchase up to 22,787 shares of common stock, for a total purchase price of $250,000 in cash. The shares and warrants were sold in units at a price per unit of $3.84, each unit consisting of one share of common stock and a warrant to purchase 0.35 of a share of common stock. The warrants have an exercise price of $6.00 per share, and a term of five years commencing from the closing of the transaction. See also note 5.

In May 2011, the Company issued 14,744 shares of its common stock, valued at $47,769, in the aggregate, to Swiss Caps as settlement of our liability for services rendered in the past.

On August 15, 2011, the Company entered into a consulting agreement with a third party (the "Advisor") for a period of nine months, pursuant to which such Advisor provided investor relations services and received a monthly cash fee and shares of the Company's common stock in that were issued in three equal installments as follows: on each of December 12, 2011, March 14, 2012 and May 15, 2012, the Company issued 6,917 shares of its common stock at fair value of $24,900, $26,560 and $24,900, respectively.

On each of March 14, 2012 and July 5, 2012, the Company issued 4,167 shares of its common stock to an advisor as remuneration for services provided. The fair value of the shares at the dates of grant was $15,500 and $16,000, respectively. See also note 9i.

In August 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 801,942 units at a purchase price of $4.44 per unit for total consideration of $3,560,192. Each unit consisted of one share of the Company's common stock and one common stock purchase warrant. Each warrant entitles the holder to purchase 0.50 a share of common stock exercisable for five years at an exercise price of $6.00 per share. The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. In addition, in August 2012, the Company entered into a Securities Purchase Agreement with an investor for the sale of 5,652 units at same terms as describe above. As the payment from said investor was received during September 2012, following which, the Company issued him its shares of common stock, the proceeds from that investment, of $25,093 are presented as shares and warrants to be issued for cash.

As to the units purchased by the Leading Investor and the amendment to the 2011 Warrants, see note 7.

The Company paid cash consideration of $71,250 as finders' fees in connection with the securities purchase agreements.

As to shares issued as part of stock based compensation plan see note 11.

As to a Clinical Trial Manufacturing Agreement with Swiss Caps, see note 11a.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph d

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7, 11A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

+ Details

STOCK BASED COMPENSATION

12 Months Ended

Aug. 31, 2012

STOCK BASED COMPENSATION [Abstract]

STOCK BASED COMPENSATION

NOTE 11 - STOCK BASED COMPENSATION:

On October 15, 2006, the Company's Board of Directors adopted the 2006 Stock Option Plan (the "2006 Stock Option Plan") for reserving a pool of 250,000 shares of the Company's common stock which may be issued at the discretion of the Company's Board of Directors from time to time.

On May 5, 2008, the Company's Board of Directors adopted the 2008 Stock Option Plan (the "2008 Stock Option Plan") for reserving a pool of 666,667 shares of the Company's common stock which may be issued at the discretion of the Company's Board of Directors from time to time.

On August 8, 2012, the Company's Board of Directors decided to cancel the 2006 Stock Option Plan, under which there were no longer any outstanding securities, and to reserve an additional 333,334 shares of the Company's common stock to the 2008 Stock Option Plan, which reflected a net increase of 83,334 shares with respect to the total amount of shares in both plans.

Under the 2008 Stock Option Plan 1,000,000 shares have been reserved for the grant of options, which may be issued at the discretion of the Company's Board of Directors from time to time. Under this Plan, each option is exercisable into one share of common stock of the Company.

The options may be exercised after vesting and in accordance with vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options is 10 years.

The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility is based on a historical volatility, by statistical analysis of the daily share price for past periods. The expected term is the length of time until the expected dates of exercising the options, based on estimated data regarding employees' exercise behavior.

The following are stock options and warrants transactions made during the years ended August 31, 2012 and 2011:

On October 30, 2006, the Company entered into a Clinical Trial Manufacturing Agreement with Swiss Caps, pursuant to which Swiss Caps would manufacture and deliver the oral insulin capsule developed by the Company. In consideration for the services being provided to the Company by Swiss Caps, the Company agreed to pay certain predetermined amounts which are to be paid in common stock of the Company, the number of shares to be issued is based on the invoice received from Swiss Caps, and the stock market price 10 days after the invoice is issued. During the year ended on August 31, 2011, the Company issued 44,220 shares of its common stock to Swiss Caps as remuneration for the services provided in the amount of $167,569. No shares were issued to Swiss Caps during the year ended on August 31, 2012.

On February 15, 2011, the Company granted options under the 2008 Stock Incentive Plan to purchase up to 20,834 shares of our common stock at an exercise price of $6.00 to a consultant. The options vest in five annual installments commencing February 16, 2012 and expire on February 16, 2021. The initial fair value of the option on the date of grant, was $62,185, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 78.65%; risk-free interest rates of 3.42%; and the remaining contractual life of 10 years. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.

In March 2011, in connection with the securities purchase agreement, as described in note 10a, the Company issued 16,397 shares of the Company's common stock and warrants to purchase 5,906 shares of common stock to three individuals, as finders' fees. The fair value of the shares at the date of grant was $59,778, and the fair value of the warrants at that date was $12,630, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 78.54% - 78.68%; risk-free interest rates of 2.11% - 2.19%; and the remaining expected term of 5 years. The warrants have an exercise price of $6.00 per share

In April 2011, the Company entered into Securities Purchase Agreements with nine accredited investors for the sale of 93,701 units at a purchase price of $3.84 per unit for total consideration of $359,800. Each unit consisted of one share of the Company's common stock and one common stock purchase warrant. Each warrant entitles the holder to purchase 0.35 a share of common stock exercisable for five years at an exercise price of $6.00 per share. The Company paid $21,588 and issued on July 2011, 5,622 warrants as finders' fees. The fair value of the warrants at that date was $11,050, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 79.28%; risk-free interest rates of 2.09%; and the remaining expected term of 5 years.

On April 27, 2011, 3,584 options were granted to ExperiMind Ltd as remuneration for services rendered at an exercise price of $6.00 per share (higher than the traded market price on the date of grant). The options vested immediately on the date of grant and will expire on April 26, 2016. The fair value of these options on the date of grant, was $10,000, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 79.24%; risk-free interest rates of 2.06%; and the remaining expected term of 5 years.

In May 2011, the Company issued 16,667 shares of its common stock, valued at $60,000, in the aggregate, to New Castle Consulting, LLC as remuneration for services rendered in the six month period that commenced on May 4, 2011.

On July 25, 2011, the Company issued warrants to purchase 2,667 shares of its common stock at an exercise price of $6.00 per share to The Trout Group, LLC as remuneration for services to be rendered during the 12 month period commencing May 13, 2011. The warrants vest in twelve equal annual installments commencing on October 13, 2011 and will expire on July 25, 2016. The fair value of these warrants on the date of grant, was $5,057, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 77.39%; risk-free interest rates of 1.55%; and the remaining expected term of 5 years. The fair value of the option as of August 31, 2012, was $4,548, using the following assumptions: dividend yield of 0% and expected term of 4 years; expected volatility of 75.41%; and risk-free interest rate of 0.45%. The fair value of the option granted is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

On August 8, 2012, an aggregate of 144,000 options was granted to Nadav Kidron, the Company's President, Chief Executive Officer and director, and Miriam Kidron, the Company's Chief Medical and Technology Officer and director, both related parties, at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant) 42,000 of the options vested immediately on the date of grant and the remainder will vest in seventeen equal monthly installments of 6,000 each. These options expire on August 7, 2022. The fair value of these options on the date of grant was $373,565, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 0.83%; and expected term of 5.5 years.

On August 8, 2012, an aggregate of 43,334 options was granted to three Board of Directors members at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant). The options vest in two equal annual installments, commencing January 1, 2013, and expire on August 7, 2022. The fair value of these options on the date of grant was $114,694, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 1.0375%; and expected term of 5.75 years.

On August 8, 2012, 50,750 options were granted to an employee of the Subsidiary, at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant). The options vest in 29 equal monthly installments of 1,750, commencing August 31, 2012, and expire on August 7, 2022. The fair value of these options on the date of grant was $134,324, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 1.0375%; and expected term of 5.75 years.

On August 8, 2012, 6,250 options were granted to an employee of the Subsidiary, at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant). The options vest in three equal annual installments, commencing January 1, 2013, and expire on August 7, 2022. The fair value of these options on the date of grant was $16,780, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 0.935%; and expected term of 6 years.

On August 8, 2012, the Company's Board of Directors approved an extension of the term of the 280,114 warrants held by Dr. Miriam Kidron by approximately two years from such approval , expiring on August 6, 2014. The incremental fair value of the warrant extension was negligible.

As to options granted to third parties, see note 9i.

The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model with the following assumptions:

	For options granted in
	the year ended August 31
	2012	2011
Expected option life (years)	5-6	5-10
Expected stock price volatility (%)	76.0	76.8-78.7
Risk free interest rate (%)	0.8-1.0	1.6-3.6
Expected dividend yield (%)	0.0	0.0

A summary of the status of the stock options granted to employees and directors as of August 31, 2012 and 2011, and changes during the years ended on those dates, is presented below:

	Year ended August 31,
	2012					2011
				Weighted				Weighted
	Number			average		Number		average
	of			exercise		of		exercise
	options			price		options		price
				$				$
Options outstanding at
beginning of year		834,117			3.84		834,117		3.84
Changes during the year:
Granted - at market price		244,334			4.08		-
Expired		(141,667	)		5.4		-
Forfeited		(4,667	)		5.64		-
Options outstanding at end
of year		932,116			3.72		834,117		3.84
Options exercisable at end
of year		717,088					743,785
Weighted average fair
value of options granted
during the year	$	3.36					-

Costs incurred in respect of stock based compensation for employees and directors, for the years ended August 31, 2012 and 2011 were $200,866 and $502,593, respectively.

The following table presents summary information concerning the options granted to employees and directors outstanding as of August 31, 2012:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	outstanding		Life		price		intrinsic value
$			Years		$		$
0.012		280,114		1.93		0.012		1,072,274
4.08 to 6.48		652,002		7.95		5.28		-
		932,116		6.14		3.72		1,072,274

The following table presents summary information concerning the options granted to employees and directors exercisable as of August 31, 2012:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	exercisable		Life		price		intrinsic value
$			Years		$		$
0.012		280,114		1.93		0.012		1,072,274
4.08 to 6.48		436,974		7.08		5.76		-
		717,088		5.07		3.48		1,072,274

As of August 31, 2012, there were $574,758 of unrecognized compensation costs related to non-vested employees and directors, to be recorded over the next 28 months.

A summary of the status of the stock options granted to non-employees as of August 31, 2012, and changes during the years ended on this date, is presented below:

	Year ended August 31
	2012				2011
			Weighted					Weighted
	Number		average		Number			average
	of		exercise		of			exercise
	options		price		options			price
			$					$
Options outstanding at
beginning of year		82,356		7.2		67,767			7.56
Changes during the year:
Granted - at market price		-				-
Granted - at an exercise
price above market
price		62,500		6.00		27,089			6.00
Expired		-				(12,500	)		(8.52	)
Options outstanding at end
of year		144,456		6.72		82,356			7.20
Options exercisable at end
of year		88,689				50,521

The Company recorded stock compensation of $117,098 and $26,733 during the years ended August 31, 2012 and 2011, respectively, related to consulting services.

The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2012:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	outstanding		Life		price		intrinsic value
$			Years		$		$
4.08 to 6.48		111,120		4.79		5.88		-
9.12		33,336		4.83		9.12		-
		144,456		4.80		6.72		-

The following table presents summary information concerning the options granted to non-employee exercisable as of August 31, 2012:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	exercisable		Life		price		intrinsic value
$			Years		$		$
4.08 to 6.48		58,131		4.15		5.88		-
9.12		30,558		5.25		9.12		-
		88,689		4.53		6.96		-

As of August 31, 2012 there were $124,948 of unrecognized compensation costs related to non-vested non-employees, to be recorded over the next 45 months.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

+ Details

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

12 Months Ended

Aug. 31, 2012

ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 12 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES:

	Year ended
	August 31,
	2012		2011

Service providers	$	580,714	$	339,052
Payroll and related expenses		16,459		36,486
	$	597,173	$	375,538

RESEARCH AND DEVELOPMENT EXPENSES, NET

12 Months Ended

Aug. 31, 2012

RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]

RESEARCH AND DEVELOPMENT EXPENSES, NET

NOTE 13 - RESEARCH AND DEVELOPMENT EXPENSES, NET:

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31,						August 31,
	2012			2011			2012

Clinical trials	$	1,298,310		$	591,733		$	5,163,353
Payroll and consulting fees		385,646			413,191			1,921,533
Costs for registration of patents		110,811			189,342			451,610
Compensation costs in respect of options granted to employees, directors and consultants		98,688			265,327			2,921,881
Other		160,350			49,444			547,608
Less - grants from the OCS and Bio Jerusalem Fund		(372,959	)		(349,728	)		(1,468,290	)
	$	1,680,845		$	1,159,309		$	9,532,694

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Audit and Accounting Guide (AAG)
-Number AAG-FGC
-Chapter 3
-Paragraph 56, 57
-IssueDate 2006-05-01
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 68
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23218-108380

+ Details

GENERAL AND ADMINISTRATIVE EXPENSES

12 Months Ended

Aug. 31, 2012

GENERAL AND ADMINISTRATIVE EXPENSES [Abstract]

GENERAL AND ADMINISTRATIVE EXPENSES

NOTE 14 - GENERAL AND ADMINISTRATIVE EXPENSES

					Period from April
					12, 2002
					(inception)
	Year ended				through
	August 31				August 31,
	2012		2011		2012

Compensation costs in respect of options granted to employees, directors and consultants	$	172,470	$	263,999	$	2,049,406
Professional services		221,218		344,277		1,899,744
Consulting fees		159,136		171,167		970,900
Travel costs		71,529		54,976		545,930
Write off of debt		-		-		275,000
Business development		284,899		151,886		815,945
Payroll and related expenses		144,101		174,229		753,208
Insurance		22,375		23,890		118,921
Other		127,436		91,536		732,493
	$	1,203,164	$	1,275,960	$	8,161,547

TAXES ON INCOME

12 Months Ended

Aug. 31, 2012

TAXES ON INCOME [Abstract]

TAXES ON INCOME

NOTE 15 - TAXES ON INCOME:

Taxes on income included in the consolidated statements of operations represent current taxes due to taxable income of the Company and its Subsidiary.

Corporate taxation in the U.S.

The applicable corporate tax rate for the Company is 35%.

As of August 31, 2012, the Company has an accumulated tax loss carryforward of approximately $4,896,605 (as of August 31, 2011, approximately $3,468,280). Under U.S. tax laws, carryforward tax losses expire 20 years after the year in which incurred. In the case of the Company the net loss carryforward will expire in the years 2025 through 2032.

Corporate taxation in Israel:

The Subsidiary is taxed in accordance with Israeli tax laws. The regular corporate tax rate in Israel for 2012 is 25%.

On December 6, 2011, the "Tax Burden Distribution Law" Legislation Amendment (2011) was published in the Official Gazette. Under this law, the previously approved gradual decrease in the corporate tax rate was cancelled. The Corporate tax rate will increase to 25% beginning 2012.

As of August 31, 2012, the Subsidiary has an accumulated tax loss carryforward of approximately $5,905,361 (as of August 31, 2011, approximately $3,328,946).

Deferred income taxes:

	August 31
	2012			2011
In respect of:
Net operating loss carryforward		3,190,152			1,813,108
Less - Valuation allowance		(3,190,152	)		(1,813,108	)
Net deferred tax assets		-,-			-,-

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a full valuation allowance.

Loss before taxes on income and income taxes included in the income statements of operations:

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31						August 31,
	2012			2011			2012
Loss before taxes on income:
U.S.		599,067			415,836			8,440,543
Outside U.S.		2,655,193			1,169,389			9,210,458
	$	3,254,260		$	1,585,225		$	17,651,001
Taxes on income:
Current:
U.S.		(7,569	)		(33,567	)		62,001
Outside U.S.		97,787			9,587			202,755
	$	90,218		$	(23,980	)	$	264,756

Reconciliation of the statutory tax benefit to effective tax expense

Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actual tax expense:

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31						August 31,
	2012			2011			2012
Loss before income taxes as reported in
the consolidated statement of operations	$	(3,254,260	)	$	(1,585,225	)	$	(17,651,001	)
Statutory tax benefit		(1,138,991	)		(554,829	)		(6,177,851	)
Increase (decrease) in income taxes
resulting from:
Change in the balance of the valuation
allowance for deferred tax losses		516,749			(58,357	)		2,762,468
Disallowable deductions		120,156			481,122			2,244,091
Increase in taxes resulting from
different tax rates applicable to
Subsidiary		502,086			132,064			1,183,796
Uncertain tax position		90,218			(23,980	)		228,272
Taxes on income for the reported year	$	90,218		$	(23,980	)	$	240,776

Uncertainty in Income Taxes

ASC No.740 "Income Taxes" requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company recognizes interest and penalties related to its tax contingencies as income tax expense. As of August 31, 2012 and 2011, the Company recorded $15,539 and $34,105, respectively, of penalties related to tax contingencies.

The following table summarizes the activity of the Company unrecognized tax benefits:

	Year ended August 31
	2012		2011
Balance at Beginning of Year	$	138,054	$	162,034
Increase (decrease) in tax positions for the current year		90,218		(23,980	)
Balance at End of Year	$	228,272	$	138,054

The Company does not expect unrecognized tax expenses to change significantly over the next 12 months.

The Company and the Subsidiary are subject to Israeli income tax examinations and to U.S. Federal income tax examinations for the tax years of 2008 through 2012. As of August 31, 2012, the Group did not record any change to its unrecognized tax benefits.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

RELATED PARTIES - TRANSACTIONS

12 Months Ended

Aug. 31, 2012

RELATED PARTIES - TRANSACTIONS

NOTE 16 - RELATED PARTIES - TRANSACTIONS:

During each of the fiscal years of 2012 and 2011 the Company paid to directors $30,000, for managerial services.

As to the agreements with Hadasit, see note 9a.

On July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY Ltd. ("KNRY"), an Israeli company owned by Nadav Kidron, whereby Mr. Nadav Kidron, through KNRY, will provide services as President and Chief Executive Officer of both Oramed and the Subsidiary (the "Nadav Kidron Consulting Agreement"). Additionally, on July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY whereby Dr. Miriam Kidron, through KNRY, will provide services as Chief Medical and Technology Officer of both Oramed and the Subsidiary (the "Miriam Kidron Consulting Agreement" and together with the Nadav Kidron Consulting Agreement, the "Consulting Agreements"). The Consulting Agreements replaced the employment agreements entered into between the Company and KNRY, dated as of August 1, 2007, pursuant to which Nadav Kidron and Miriam Kidron, respectively, provided services to the Company and the Subsidiary. The Consulting Agreements are both terminable by either party upon 60 days prior written notice. The Consulting Agreements provide that KNRY (i) will be paid, under each of the Consulting Agreements, in NIS a gross amount of NIS50,400 per month (as of August 31, 2012 the monthly payment in the Company's functional currency is $12,512) and (ii) will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements.

As to options granted to related parties, see note 11h.

According to the JV Agreement (note 5), Entera rented office space and services from the Subsidiary for a period of up to 24 months commencing August 19, 2010, for a non-refundable, up-front fee in the amount of $36,000. The rent period ended on March 31, 2011, when the JV Agreement was terminated.

According to the JV agreement (note 5), the subsidiary of the Company provided accounting services to Entera at a monthly fee in the amount of NIS 3,500 ($869). These services were ceased on March 31, 2011, when the JV agreement was terminated.

Balances with related parties:

	August 31
	2012		2011
Accounts Receivables - KNRY	$	404		-
Accounts payable and accrued expenses - KNRY		-	$	18,502

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph k

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 3A
-Section 04
-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

SUBSEQUENT EVENTS

3 Months Ended

12 Months Ended

Nov. 30, 2012

Aug. 31, 2012

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS

NOTE 6 - SUBSEQUENT EVENTS:

On December 20, 2012, 20,000 options were granted to a director at an exercise price of $6.00 per share (higher than the traded market price on the date of grant). The options vest in two equal annual installments, commencing January 1, 2013, and expire on December 19, 2022. The fair value of these options on the date of grant was $41,402, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 64.35%; risk-free interest rates of 1.01%; and expected term of 5.75 years.

On December 20, 4,667 options were granted to an employee of the Subsidiary, at an exercise price of $6.00 per share (higher than the traded market price on the date of grant). The options vest in two annual installments of 2,334 and 2,333, commencing June 1, 2013, and expire on December 19, 2022. The fair value of these options on the date of grant was $9,660, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 64.35%; risk-free interest rates of 1.01%; and expected term of 5.75 years.

On January 10, 2013, the Company's board of directors have approved a reverse stock split at a ratio of one-for-twelve, effective January 22, 2013, which decreased the number of common shares issued and outstanding as of November 30, 2012, from approximately 86.5 million shares to approximately 7.2 million shares and the number of authorized common shares from approximately 200 million shares to approximately 16.7 million shares. All share and per share amounts included in the consolidated financial statements have been adjusted retroactively to reflect the effects of the reverse stock split.

NOTE 17 - SUBSEQUENT EVENTS:

In September 2012, the Company issued 5,652 shares of its common stock and 2,826 common stock purchase warrant to an investor. See also note 10g.

Between September and November 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 329,832 units at a purchase price of $4.44 per unit for total consideration of $1,464,425. Each unit consisted of one share of the Company's common stock and one common stock purchase warrant. Each warrant entitles the holder to purchase 0.50 a share of common stock exercisable for five years at an exercise price of $6.00 per share. The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. In addition, the Leading Investor, who purchased 405,405 of the units, was granted the right to maintain its percentage of the shares of the Company's common stock outstanding by purchasing more shares whenever the Company proposes to issue certain additional shares to other investors. Such right only exists so long as such investor holds at least 5% of the Company's outstanding common stock. In addition, such investor's warrants contain full ratchet anti-dilution protection and cashless exercise provisions not contained in the other investors' warrants. The terms of the Leading Investor's Securities Purchase Agreement are substantially the same as those from 2011. See note 10a above.

As finder's fee, in connection with the securities purchase agreements, the Company paid cash consideration of $5,385 and might be required to pay additional $7,500, as well as issued 1,127 shares of the Company's common stock 564 common stock purchase warrant for other individual. The Company will also issue 12,745 shares of the Company's common stock and 6,373 common stock purchase warrant to a director as finder's fee with respect to the Securities Purchase Agreements described above and in note 10g.

On October 30, 2012, the Company entered into a Securities Purchase Agreement with D.N.A, according to which, the Company issued on that day to D.N.A 199,172 shares of its common stock, valued at approximately $628,630 at the day of the transaction, in consideration for the option to purchase up to 21,637,611 ordinary shares of D.N.A with no additional cost. Following the exercise of the option by the Company, it will hold approximately 14.5% of D.N.A shareholders equity, including D.N.A shares that were received in March 2011, see note 5.

In addition, as a result of this agreement with D.N.A, and pursuant to the adjustment terms of the 2011 Warrants held by the Leading Investor, as described in note 10a and 10g, the Company further amended the 2011 Warrants by: (i) reducing the exercise price from $0.37 to $0.3138 and (ii) increasing the number of shares issuable upon the exercise of the 2011 Warrants from 2,956,081 to 3,485,500.

On November 29, 2012, the Company and the Leading Investor entered into a letter agreement (the "Agreement") in connection with three warrants issued by the Company to the Leading Investor in January 2011, August 2012 and November 2012 (together, the "Three Warrants"). Pursuant to the Agreement, the Company and the Leading Investor agreed to amend the Three Warrants to provide that the anti-dilution protection of each of the Three Warrants shall be removed in its entirety. In addition, as to the Warrants issued in August and November 2012, the parties agreed that the exercise price shall be reduced to $3.7656. On that day, the Company also issued to the Leading Investor a Common Stock Purchase Warrant (the "New Warrant") pursuant to which, the Leading Investor shall have the right to purchase up to 137,311 shares of the common stock of the Company over a period of four years at an exercise price of $7.2 per share.

In addition to the New Warrant, Nadav Kidron, the Company's President, Chief Executive Officer and director, in his personal capacity as a shareholder of the Company, undertook and agreed that following the execution and delivery of the Agreement, in the event that an adjustment pursuant to the anti-dilution protection of any of the Three Warrants (had it not been amended by the Agreement thereof) would have been triggered and the number of shares of common stock of the Company that the Leading Investor would have been able to purchase under the Three Warrants would have increased by an aggregate number in excess of 137,311 shares, then the Leading Investor shall have the right to purchase from Mr. Kidron such number of shares of common stock of the Company owned by Mr. Kidron equal to such excess, up to a maximum of 112,690 shares of common stock of the Company at an exercise price of $3.7656. The foregoing right shall survive until the termination of such Three Warrants.

On January 10, 2013, the Company's board of directors have approved a reverse stock split at a ratio of one-for-twelve, effective January 22, 2013, which decreased the number of common shares issued and outstanding as of August 31, 2012, from approximately 80.1 million shares to approximately 6.7 million shares and the number of authorized common shares from approximately 200 million shares to approximately 16.7 million shares. All share and per share amounts included in the consolidated financial statements have been adjusted retroactively to reflect the effects of the reverse stock split.

SIGNIFICANT ACCOUNTING POLICIES (Policy)

3 Months Ended

12 Months Ended

Nov. 30, 2012

Aug. 31, 2012

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

General

General:

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

The Company has been in the development stage since its formation and has not yet generated any revenues from its operations.

The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with the ASC Topic 915 "Development Stage Entities".

General

Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd ("Hadasit") (the "First Agreement") to acquire the provisional patent related to orally ingestible insulin pill to be used for the treatment of individuals with diabetes, see also note 9a.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

The Company has been in the development stage since its formation and has not yet generated any revenues from its operations.

The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with the ASC Topic 915 "Development Stage Entities".

Accounting principles

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").

Use of estimates in the preparation of financial statements

Functional currency

d.	Functional currency

The currency of the primary economic environment in which the operations of the Group are conducted is the U.S. dollar ("$" or "dollar").

Most of the group's operating expenses are incurred in dollars. Thus, the functional currency of the Group is the dollar.

Principles of consolidation

Condensed Consolidated Financial Statements Preparation

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.

Property and equipment

f.	Property and equipment

Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the assets.

Annual rates of depreciation are as follows:

		%
Computers and peripheral equipment		33
Office furniture and equipment		15-33

Leasehold improvements are amortized over the term of the lease which is shorter than the estimated useful life of the improvements.

Income taxes

Deferred taxes

Uncertainty in income tax

Research and development

Research and development, net

Cash equivalents

Comprehensive loss

The Company has no other comprehensive loss components other than net loss for the fiscal years of 2012 and 2011.

Loss per common share

k.	Loss per common share

Impairment in value of long-lived assets

Stock based compensation

m.	Stock based compensation

Warrants issued as part of capital raisings that are classified as a liability

n.	Warrants issued as part of capital raisings that are classified as a liability

Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) are classified as liabilities in the statement of financial position.

The liability is measured both initially and in subsequent periods in fair value, with changes in fair value charged to finance expenses, net. See note 7.

Fair value measurement

o.	Fair value measurement:

Level 1:

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:

Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3:

Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of August 31, 2012 the assets or liabilities measured at fair value comprise of:

- available for sale securities (level 1).

- warrants (level 3).

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent.

In order to secure the fulfillment of the Company's obligations under the derivatives agreements, the Company has placed a restricted deposit with the bank in an amount of $16,000.

Concentration of credit risks

p.	Concentration of credit risks

Newly issued and recently adopted accounting pronouncements

Newly issued and recently adopted Accounting Pronouncements

Newly issued and recently adopted accounting pronouncements:

In June 2011, the FASB issued an update to ASC No. 220, "Presentation of Comprehensive Income," which eliminates the option to present other comprehensive income and its components in the statement of shareholders' equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The accounting update will be applicable to the Company beginning in the first quarter of fiscal year 2013. The adoption of the new guidance is not expected to have a material impact on the consolidated financial statements.

Reclassifications

Certain figures in respect of prior years have been reclassified to conform to the current year presentation.

r.	Reclassifications

Certain figures in respect of prior years have been reclassified to conform to the current year presentation.

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Aug. 31, 2012

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Schedule of Annual Depreciation Rates

		%
Computers and peripheral equipment		33
Office furniture and equipment		15-33

SHORT TERM INVESTMENTS (Tables)

12 Months Ended

Aug. 31, 2012

SHORT TERM INVESTMENTS [Abstract]

Schedule of Short Term Investments

	August 31
	2012			2011
	Annual interest rate	Amount		Annual interest rate	Amount
Dollars deposits	0.85%	$	260,371	0.7-0.86%	$	1,801,400
NIS deposits	1.93-1.97%		194,010			-
		$	454,381		$	1,801,400

MARKETABLE SECURITIES (Tables)

3 Months Ended

12 Months Ended

Nov. 30, 2012

Aug. 31, 2012

MARKETABLE SECURITIES [Abstract]

Schedule of Marketable Securities Carried at Fair Value

	Level 1		Level 3		Total
Marketable securities:
November 30, 2012	$	317,657	$	747,151	$	1,064,808
August 31, 2012	$	200,311		-	$	200,311

	Level 1		Level 3		Total
Marketable securities:
August 31, 2012	$	200,311		-	$	200,311
August 31, 2011		-	$	384,565	$	384,565

Schedule of Financial Assets Measured Using Unobservable Inputs

	Three months ended
	November, 30
	2012
	Unaudited
Carrying value at the beginning of the period	$	-
Additions		628,630
Changes in fair value		118,521
Carrying value at the end of the period	$	747,151

	August 31
	2012			2011
Carrying value at the beginning of the period	$	384,565		$	-
Additions - see note 5		-			581,977
Reclassification to level 1		(384,565	)		-
Impairment of available-for-sale securities - financial expenses		-			(197,412	)
Carrying value at the end of the period	$	-		$	384,565

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring and/or nonrecurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References + Details

- Definition

Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.

+ References + Details

ACCOUNTS RECEIVABLE (Tables)

12 Months Ended

Aug. 31, 2012

ACCOUNTS RECEIVABLE [Abstract]

Schedule of Accounts Receivable

	August 31
	2012		2011

Receivables from D.N.A (see note 5)	$	-	$	450,844
Tax Authorities		53,341		32,406
Other receivables		34,350		59,641
	$	87,691	$	542,891

AGREEMENT WITH D.N.A BIOMEDICAL SOLUTIONS LTD (Tables)

12 Months Ended

Aug. 31, 2012

AGREEMENTS WITH D.N.A. BIOMEDICAL SOLUTIONS LTD [Abstract]

Schedule of Gain on Sale of Investment

Fair value of D.N.A Shares	$	581,977
Receivables from D.N.A		450,000
Re-classification of currency translation adjustments		7,930
	$	1,039,907
Less - net cost of the investment realized		(6,903	)
	$	1,033,004

- Definition

Tabular disclosure of the realized and unrealized gains and losses reported in the statement of income which have resulted from the sale and holding of marketable securities, respectively, as well as the sale or disposal of cost method investments. Such amounts would include realized gains and losses on the sale or disposal of trading, available-for-sale, and held-to-maturity securities, unrealized gains and losses on trading securities, unrealized gains and losses on available-for-sale and held-to-maturity securities transferred to the trading securities category, realized gains and losses on the sale or disposal of cost method investments, and losses recognized for other than temporary impairments (OTTI) of such investments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 21
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 7, 13, 16, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section M

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6379932&loc=d3e22054-111558

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (c)-(e)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.M)
-URI http://asc.fasb.org/extlink&oid=6784337&loc=d3e87990-122713

+ Details

PROPERTY AND EQUIPMENT, NET (Tables)

12 Months Ended

Aug. 31, 2012

PROPERTY AND EQUIPMENT, Net [Abstract]

Schedule of Property and Equipment

	August 31
	2012		2011
Cost:
Leasehold improvements	$	76,029	$	76,029
Office furniture and equipment		19,941		19,941
Computers and peripheral equipment		29,642		27,513
		125,612		123,483
Less - accumulated depreciation and amortization		120,844		106,107
	$	4,768	$	17,376

WARRANTS (Tables)

3 Months Ended

12 Months Ended

Nov. 30, 2012

Aug. 31, 2012

WARRANTS [Abstract]

Schedule of Warrants Carried at Fair Value

	Fair value measurements at reporting date using
	Level 3		Total
Warrants -
August 31, 2012	$	637,182	$	637,182

	Fair value measurements at reporting date using
	Level 3		Total
Warrants -
August 31, 2012	$	637,182	$	637,182

Schedule of Liabilities Measured at Fair Value Using Significant Unobservable Inputs

	Three months ended November 30
	2012
Carrying value at the beginning of the period	$	637,182
Additional warrant liabilities granted		28,344
Changes in fair value of warrant liabilities		(44,699	)
Exchange of warrants		(620,827	)
Carrying value at the end of the period	$	-

	August 31
	2012
Carrying value at the beginning of the period		-
Additions	$	494,478
Changes in fair value of warrant liabilities		142,704
Carrying value at the end of the period	$	637,182

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring and/or nonrecurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details

STOCK BASED COMPENSATION (Tables)

12 Months Ended

Aug. 31, 2012

STOCK BASED COMPENSATION [Abstract]

Schedule of Fair Value Assumptions

	For options granted in
	the year ended August 31
	2012	2011
Expected option life (years)	5-6	5-10
Expected stock price volatility (%)	76.0	76.8-78.7
Risk free interest rate (%)	0.8-1.0	1.6-3.6
Expected dividend yield (%)	0.0	0.0

Schedule of Stock Option Activity for Employees

	Year ended August 31,
	2012					2011
				Weighted				Weighted
	Number			average		Number		average
	of			exercise		of		exercise
	options			price		options		price
				$				$
Options outstanding at
beginning of year		834,117			3.84		834,117		3.84
Changes during the year:
Granted - at market price		244,334			4.08		-
Expired		(141,667	)		5.4		-
Forfeited		(4,667	)		5.64		-
Options outstanding at end
of year		932,116			3.72		834,117		3.84
Options exercisable at end
of year		717,088					743,785
Weighted average fair
value of options granted
during the year	$	3.36					-

Summary of Information for Options Granted and Exercisable for Employees

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	outstanding		Life		price		intrinsic value
$			Years		$		$
0.012		280,114		1.93		0.012		1,072,274
4.08 to 6.48		652,002		7.95		5.28		-
		932,116		6.14		3.72		1,072,274

The following table presents summary information concerning the options granted to employees and directors exercisable as of August 31, 2012:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	exercisable		Life		price		intrinsic value
$			Years		$		$
0.012		280,114		1.93		0.012		1,072,274
4.08 to 6.48		436,974		7.08		5.76		-
		717,088		5.07		3.48		1,072,274

Schedule of Stock Option Activity for Non-Employees

	Year ended August 31
	2012				2011
			Weighted					Weighted
	Number		average		Number			average
	of		exercise		of			exercise
	options		price		options			price
			$					$
Options outstanding at
beginning of year		82,356		7.2		67,767			7.56
Changes during the year:
Granted - at market price		-				-
Granted - at an exercise
price above market
price		62,500		6.00		27,089			6.00
Expired		-				(12,500	)		(8.52	)
Options outstanding at end
of year		144,456		6.72		82,356			7.20
Options exercisable at end
of year		88,689				50,521

Summary of Information for Options Granted and Exercisable for Non-Employees

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	outstanding		Life		price		intrinsic value
$			Years		$		$
4.08 to 6.48		111,120		4.79		5.88		-
9.12		33,336		4.83		9.12		-
		144,456		4.80		6.72		-

The following table presents summary information concerning the options granted to non-employee exercisable as of August 31, 2012:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	exercisable		Life		price		intrinsic value
$			Years		$		$
4.08 to 6.48		58,131		4.15		5.88		-
9.12		30,558		5.25		9.12		-
		88,689		4.53		6.96		-

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

12 Months Ended

Aug. 31, 2012

ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]

Schedule of Accounts Payable and Accrued Expenses

	Year ended
	August 31,
	2012		2011

Service providers	$	580,714	$	339,052
Payroll and related expenses		16,459		36,486
	$	597,173	$	375,538

RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)

12 Months Ended

Aug. 31, 2012

RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]

Schedule of Research and Development Expenses

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31,						August 31,
	2012			2011			2012

Clinical trials	$	1,298,310		$	591,733		$	5,163,353
Payroll and consulting fees		385,646			413,191			1,921,533
Costs for registration of patents		110,811			189,342			451,610
Compensation costs in respect of options granted to employees, directors and consultants		98,688			265,327			2,921,881
Other		160,350			49,444			547,608
Less - grants from the OCS and Bio Jerusalem Fund		(372,959	)		(349,728	)		(1,468,290	)
	$	1,680,845		$	1,159,309		$	9,532,694

- Definition

Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.

+ References + Details

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)

12 Months Ended

Aug. 31, 2012

GENERAL AND ADMINISTRATIVE EXPENSES [Abstract]

Schedule of General and Administrative Expenses

					Period from April
					12, 2002
					(inception)
	Year ended				through
	August 31				August 31,
	2012		2011		2012

Compensation costs in respect of options granted to employees, directors and consultants	$	172,470	$	263,999	$	2,049,406
Professional services		221,218		344,277		1,899,744
Consulting fees		159,136		171,167		970,900
Travel costs		71,529		54,976		545,930
Write off of debt		-		-		275,000
Business development		284,899		151,886		815,945
Payroll and related expenses		144,101		174,229		753,208
Insurance		22,375		23,890		118,921
Other		127,436		91,536		732,493
	$	1,203,164	$	1,275,960	$	8,161,547

TAXES ON INCOME (Tables)

12 Months Ended

Aug. 31, 2012

TAXES ON INCOME [Abstract]

Schedule of Deferred Income Taxes

	August 31
	2012			2011
In respect of:
Net operating loss carryforward		3,190,152			1,813,108
Less - Valuation allowance		(3,190,152	)		(1,813,108	)
Net deferred tax assets		-,-			-,-

Schedule of Income Taxes Included in the Income Statements

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31						August 31,
	2012			2011			2012
Loss before taxes on income:
U.S.		599,067			415,836			8,440,543
Outside U.S.		2,655,193			1,169,389			9,210,458
	$	3,254,260		$	1,585,225		$	17,651,001
Taxes on income:
Current:
U.S.		(7,569	)		(33,567	)		62,001
Outside U.S.		97,787			9,587			202,755
	$	90,218		$	(23,980	)	$	264,756

Schedule of Reconciliation of Income Taxes

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31						August 31,
	2012			2011			2012
Loss before income taxes as reported in
the consolidated statement of operations	$	(3,254,260	)	$	(1,585,225	)	$	(17,651,001	)
Statutory tax benefit		(1,138,991	)		(554,829	)		(6,177,851	)
Increase (decrease) in income taxes
resulting from:
Change in the balance of the valuation
allowance for deferred tax losses		516,749			(58,357	)		2,762,468
Disallowable deductions		120,156			481,122			2,244,091
Increase in taxes resulting from
different tax rates applicable to
Subsidiary		502,086			132,064			1,183,796
Uncertain tax position		90,218			(23,980	)		228,272
Taxes on income for the reported year	$	90,218		$	(23,980	)	$	240,776

Schedule of Unrecognized Tax Benefits

	Year ended August 31
	2012		2011
Balance at Beginning of Year	$	138,054	$	162,034
Increase (decrease) in tax positions for the current year		90,218		(23,980	)
Balance at End of Year	$	228,272	$	138,054

RELATED PARTIES - TRANSACTIONS (Tables)

12 Months Ended

Aug. 31, 2012

Schedule of Balances with Related Parties

	August 31
	2012		2011
Accounts Receivables - KNRY	$	404		-
Accounts payable and accrued expenses - KNRY		-	$	18,502

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Aug. 31, 2012	Aug. 31, 2011
Fair value measurement
Restricted deposit	$ 16,000
Computers and Peripheral Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate	33.00%
Office Furniture and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate	15.00%
Office Furniture and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate	33.00%
Stock Options And Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,892,171	1,266,700

SHORT TERM INVESTMENTS (Details) - USD ($)	Aug. 31, 2012	Aug. 31, 2011
Short Term Investments [Line Items]
Amount	$ 454,381	$ 1,801,400
Dollars deposits [Member]
Short Term Investments [Line Items]
Interest rate	0.85%
Amount	$ 260,371	$ 1,801,400
Dollars deposits [Member] \| Minimum [Member]
Short Term Investments [Line Items]
Interest rate		0.70%
Dollars deposits [Member] \| Maximum [Member]
Short Term Investments [Line Items]
Interest rate		0.86%
NIS deposits [Member]
Short Term Investments [Line Items]
Amount	$ 194,010
NIS deposits [Member] \| Minimum [Member]
Short Term Investments [Line Items]
Interest rate	1.93%
NIS deposits [Member] \| Maximum [Member]
Short Term Investments [Line Items]
Interest rate	1.97%

MARKETABLE SECURITIES (Details) - USD ($)	3 Months Ended	12 Months Ended
MARKETABLE SECURITIES (Details) - USD ($)	Nov. 30, 2012	Aug. 31, 2012	Aug. 31, 2011
MARKETABLE SECURITIES [Abstract]
Carrying value at the beginning of the period		$ 384,565
Additions - see note 5	628,630		$ 581,977
Reclassification to level 1		(384,565)
Impairment of available-for-sale securities - financial expenses			(197,412)
Carrying value at the end of the period	747,151		384,565
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	1,064,808	200,311	384,565
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	317,657	200,311
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 747,151		$ 384,565

- Definition

This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale.

+ References + Details

ACCOUNTS RECEIVABLE (Details) - USD ($)	Nov. 30, 2012	Aug. 31, 2012	Aug. 31, 2011
ACCOUNTS RECEIVABLE [Abstract]
Receivables from D.N.A. (see note 5)			$ 450,844
Tax Authorities		53,341	32,406
Other receivables		34,350	59,641
Total accounts receivable	$ 75,950	$ 87,691	$ 542,891

- Definition

Amounts due from an entity in which the reporting entity shares joint control with another party or group, due within 1 year (or 1 business cycle).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph k
-Subparagraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 2
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3
-Subparagraph a
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

+ Details

- Definition

Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.

+ References + Details

AGREEMENT WITH D.N.A BIOMEDICAL SOLUTIONS LTD (Narrative) (Details)	1 Months Ended			3 Months Ended		4 Months Ended	12 Months Ended		125 Months Ended	128 Months Ended
	Apr. 30, 2011 USD ($)	Mar. 31, 2011 USD ($) $ / warrants shares	Jun. 30, 2010 USD ($)	Nov. 30, 2012 USD ($)	Nov. 30, 2011 USD ($)	Feb. 28, 2011 USD ($) $ / warrants	Aug. 31, 2012 USD ($) $ / warrants	Aug. 31, 2011 USD ($)	Aug. 31, 2012 USD ($) $ / warrants	Nov. 30, 2012 USD ($)	Oct. 30, 2012 shares	Sep. 30, 2012 shares	Aug. 28, 2012 $ / warrants shares	Feb. 22, 2011	Jan. 31, 2011 $ / warrants shares
Related Party Transaction [Line Items]
Shares issued for Entera, value								$ 581,977
Impairment of available-for-sale securities							$ 184,254	197,412	$ 381,666	$ 381,666
Number of shares authorized by warrant \| shares												2,826	246,341		182,292
Exercise price per share \| $ / warrants		6.0				6.0	6.0		6.0				4.44		6.0
Proceeds from issuance of shares	$ 359,800			$ 1,458,436		$ 3,106,000	$ 3,488,942	3,694,212	$ 15,144,635	$ 16,603,071
Entera Bio Ltd. [Member]
Related Party Transaction [Line Items]
Royalty percentage							3.00%		3.00%
D.N.A. Biomedical Solutions Ltd. [Member]
Related Party Transaction [Line Items]
Impairment of available-for-sale securities							$ 184,254	$ 197,412
Number of shares to be sold \| shares		65,104									199,172
Number of shares authorized by warrant \| shares		22,787
Exercise price per share \| $ / warrants		6.0
Proceeds from issuance of shares		$ 250,000
D.N.A. Biomedical Solutions Ltd. [Member] \| Entera Bio Ltd. [Member]
Related Party Transaction [Line Items]
Investment amount			$ 600,000
Percentage of shares acquired			50.00%
Share purchase agreement, percentage of shares														47.00%
Promissory note, principal amount		$ 450,000
Promissory note, interest rate		0.45%
Shares issued for Entera, shares \| shares		8,404,667
Shares issued for Entera, value		$ 581,977

AGREEMENT WITH D.N.A BIOMEDICAL SOLUTIONS LTD (Schedule of Gain on Sale of Investment) (Details) - USD ($)	3 Months Ended		12 Months Ended		125 Months Ended	128 Months Ended
	Nov. 30, 2012	Nov. 30, 2011	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012	Nov. 30, 2012
AGREEMENTS WITH D.N.A. BIOMEDICAL SOLUTIONS LTD [Abstract]
Fair value of D.N.A. shares				$ 581,977
Receivables from D.N.A.				450,000
Re-classification of currency translation adjustments				7,930
Investment, before cost				1,039,907
Less - net cost of the investment realized				(6,903)
Gain on sale of investment				$ 1,033,004	$ 1,033,004	$ 1,033,004

- Definition

This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting.

+ References + Details

PROPERTY AND EQUIPMENT, NET (Details) - USD ($)	3 Months Ended		12 Months Ended		125 Months Ended	128 Months Ended
PROPERTY AND EQUIPMENT, NET (Details) - USD ($)	Nov. 30, 2012	Nov. 30, 2011	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012	Nov. 30, 2012
Property, Plant and Equipment [Line Items]
Cost			$ 125,612	$ 123,483	$ 125,612
Less - accumulated depreciation and amortization			120,844	106,107	120,844
Property and equipment, net	$ 2,497		4,768	17,376	4,768	$ 2,497
Depreciation expenses	$ 2,271	$ 6,042	14,737	28,303	120,844	$ 123,115
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Cost			76,029	76,029	76,029
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost			19,941	19,941	19,941
Computers and Peripheral Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost			$ 29,642	$ 27,513	$ 29,642

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References + Details

WARRANTS (Details)		1 Months Ended							3 Months Ended		4 Months Ended	12 Months Ended		125 Months Ended	128 Months Ended
WARRANTS (Details)	Nov. 29, 2012 USD ($) $ / warrants shares	Dec. 20, 2012 USD ($)	Nov. 30, 2012 $ / warrants shares	Aug. 31, 2012 USD ($) $ / warrants shares	Jul. 31, 2011 USD ($)	Apr. 30, 2011	Mar. 31, 2011 $ / warrants	Jan. 31, 2011 $ / warrants shares	Nov. 30, 2012 USD ($) $ / warrants	Nov. 30, 2011 USD ($)	Feb. 28, 2011 $ / warrants	Aug. 31, 2012 USD ($) $ / warrants shares	Aug. 31, 2011 USD ($)	Aug. 31, 2012 USD ($) $ / warrants shares	Nov. 30, 2012 USD ($) $ / warrants	Oct. 30, 2012 $ / warrants shares	Sep. 30, 2012 shares	Aug. 28, 2012 $ / warrants shares
WARRANTS [Abstract]
Carrying value at the beginning of the period									$ 637,182
Additions									28,344			494,478
Changes in fair value of warrant liabilities									(44,699)			142,704
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants				$ 637,182								$ 637,182		$ 637,182
Warrants [Line Items]
Warrant term				5 years		5 years		5 years			5 years
Number of shares authorized by warrant \| shares								182,292									2,826	246,341
Exercise price per share \| $ / warrants				6.0			6.0	6.0			6.0	6.0		6.0				4.44
Fair value of options granted					$ 11,050
Expected dividend yield (%)					0.00%		0.00%					0.00%	0.00%
Remaining contractual life					5		5
Expected volatility					79.28%
Risk-free interest rate					2.09%
Financial expense									$ 299,158	$ 19,556		$ 199,123	$ 18,780	$ 380,380	$ 679,538
2011 Warrants [Member]
Warrants [Line Items]
Number of shares authorized by warrant \| shares				246,341				182,292				246,341		246,341		290,459
Exercise price per share \| $ / warrants				4.44				6.0				4.44		4.44		3.7656
Three Warrants [Member]
Warrants [Line Items]
Number of warrants granted \| shares			16,892	112,613				182,292
Warrant term			5 years	5 years				5 years
Exercise price per share \| $ / warrants	3.7656		6.0	6.0				6.0	6.0			6.0		6.0	6.0
Financial expense									$ 296,982
New Warrant [Member]
Warrants [Line Items]
Warrant term	4 years
Number of shares authorized by warrant \| shares	137,311
Exercise price per share \| $ / warrants	7.2
Fair value of options granted	$ 145,173
Expected dividend yield (%)	0.00%
Remaining contractual life	4
Expected volatility	62.29%
Risk-free interest rate	0.57%
Kidron Option [Member]
Warrants [Line Items]
Number of shares authorized by warrant \| shares	112,690
Fair value of options granted	$ 168,220
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants				$ 637,182								$ 637,182		$ 637,182

EMPLOYEES RIGHTS UPON RETIREMENT (Details) - USD ($)	12 Months Ended
EMPLOYEES RIGHTS UPON RETIREMENT (Details) - USD ($)	Aug. 31, 2012	Aug. 31, 2011
EMPLOYEE RIGHTS UPON TERMINATION [Abstract]
Severance pay insurance deposits	$ 3,620	$ 3,275
Severance pay expenses	5,615	10,241
Severance pay expenses in respect of Contribution Plan	7,089	$ 6,966
Severance pay expected deposit	10,155
Severance pay expected liability to Contribution Plan	$ 7,619

- Definition

The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a benefit arrangement associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination or a discontinued operation as defined by generally accepted accounting principles and costs associated with one-time termination benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS146-1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5-8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 112
-Paragraph 7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
-Paragraph 8-13, 20
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140864-122747

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140904-122747

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(10)
-URI http://asc.fasb.org/extlink&oid=6962843&loc=d3e1928-114920

+ Details

COMMITMENTS (Details)					1 Months Ended					3 Months Ended		4 Months Ended	12 Months Ended		125 Months Ended	128 Months Ended
COMMITMENTS (Details)	Aug. 08, 2012 USD ($)	Aug. 15, 2011	Feb. 15, 2011 USD ($) $ / warrants shares	Feb. 10, 2010 USD ($)	Aug. 31, 2012 USD ($) $ / warrants	Jul. 31, 2011 USD ($)	Apr. 30, 2011	Mar. 31, 2011 $ / warrants	Jan. 31, 2011 $ / warrants shares	Nov. 30, 2012 USD ($) shares	Nov. 30, 2011 USD ($)	Feb. 28, 2011 $ / warrants	Aug. 31, 2012 USD ($) $ / warrants	Aug. 31, 2011 USD ($)	Aug. 31, 2012 USD ($) $ / warrants	Nov. 30, 2012 USD ($) shares	Sep. 30, 2012 shares	Sep. 27, 2012 USD ($)	Aug. 28, 2012 $ / warrants shares	Jun. 22, 2011 USD ($)	Apr. 21, 2009 USD ($)	Feb. 17, 2006
Related Party Transaction [Line Items]
Professional services													$ 221,218	$ 344,277	$ 1,899,744
Accounts payable																		$ 3,500,000
Number of shares authorized by warrant \| shares									182,292								2,826		246,341
Warrant term					5 years		5 years		5 years			5 years
Exercise price per share \| $ / warrants					6.0			6.0	6.0			6.0	6.0		6.0				4.44
Fair value of options granted						$ 11,050
Expected dividend yield (%)						0.00%		0.00%					0.00%	0.00%
Expected volatility						79.28%
Risk-free interest rate						2.09%
Remaining contractual life						5		5
Research and development expenses										$ 392,626	$ 184,016		$ 1,680,845	$ 1,159,309	$ 9,532,694	$ 9,925,320
SAFC Pharma [Member]
Related Party Transaction [Line Items]
Purchase order																				$ 600,000
First Agreement With Hadasit [Member]
Related Party Transaction [Line Items]
Management fee percentage																						10.00%
Bio-Jerusalem [Member]
Related Party Transaction [Line Items]
Royalty percentage					4.00%					4.00%			4.00%		4.00%	4.00%
Royalty percentage, maximum percentage of grants received					100.00%					100.00%			100.00%		100.00%	100.00%
Capital raise amount										$ 12,320						$ 12,320
Accounts payable										65,053						$ 65,053
Research and development expenses															$ 52,733
ADRES [Member]
Related Party Transaction [Line Items]
Professional services										160,000
Commitments for consulting service, amount specified to be paid in monthly fixed fees																					$ 110,000
Commitments for consulting service, monthly fixed fee																					10,000
Commitments for consulting service, amount to be paid after milestone achievement																					$ 51,000
Consulting fees paid for first three milestones										50,000
Vetgenerics Research G. Ziv Ltd [Member]
Related Party Transaction [Line Items]
Commitments for consulting services				$ 154,320
Research and development expenses													$ 129,570
Advisor [Member]
Related Party Transaction [Line Items]
Commitments for consulting services, time period			P1Y
Shares to be issued for services \| shares			25,000
Number of shares authorized by warrant \| shares			62,500
Exercise price per share \| $ / warrants			6.0
Warrants vesting, number of installments			12
Fair value of options granted			$ 121,304							$ 105,455
Expected dividend yield (%)			0.00%							0.00%
Expected volatility			76.82%							74.64%
Risk-free interest rate			0.81%							0.55%
Remaining contractual life			5							4.2
Consultant [Member]
Related Party Transaction [Line Items]
Commitments for consulting services, time period		9 months	5 years
Commitments for consulting service, monthly fixed fee			$ 8,000
Royalty percentage			8.00%
Number of shares authorized by warrant \| shares			20,834
Exercise price per share \| $ / warrants			12.0
Warrants vesting, number of installments			5
Fair value of options granted			$ 62,185										$ 54,345
Expected dividend yield (%)			0.00%										0.00%
Expected volatility			78.65%										75.41%
Risk-free interest rate			3.62%										1.29%
Remaining contractual life			10										8.5
Dr. Michael Berelowitz M.D. [Member]
Related Party Transaction [Line Items]
Number of shares authorized by warrant \| shares										6,373						6,373
Warrants vesting, number of installments	2
Fair value of options granted	$ 114,694
Expected dividend yield (%)	0.00%
Expected volatility	76.03%
Risk-free interest rate	1.0375%
Remaining contractual life	5.75
Chief Scientist Office [Member]
Related Party Transaction [Line Items]
Royalty percentage, maximum percentage of grants received					100.00%								100.00%		100.00%
Capital raise amount										$ 1,332,374						$ 1,332,374
Research and development expenses										$ 22,378			$ 372,959	296,995	$ 1,415,557
Chief Scientist Office [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Royalty percentage					3.00%								3.00%		3.00%
Chief Scientist Office [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Royalty percentage					3.50%								3.50%		3.50%
Vehicles Lease [Member]
Long-term Purchase Commitment [Line Items]
Operating lease term													3 years
Lease expenses													$ 29,543	$ 37,144
Future lease payments due in 2012					$ 21,201								21,201		$ 21,201
Future lease payments due in 2013					8,237								8,237		8,237
Future lease payments due in 2014					686								686		686
Deposit for lease agreement													$ 7,840
Office Facilities Lease [Member]
Long-term Purchase Commitment [Line Items]
Operating lease term										57 months			57 months
Monthly lease payment										$ 892			$ 844
Future lease payments due in 2012					11,768					12,441			11,768		11,768	12,441
Future lease payments due in 2013					15,338					16,215			15,338		15,338	16,215
Future lease payments due in 2014					$ 16,713					$ 17,669			$ 16,713		$ 16,713	$ 17,669

STOCK HOLDERS' EQUITY (Details)					1 Months Ended					3 Months Ended		4 Months Ended	12 Months Ended					65 Months Ended	125 Months Ended	128 Months Ended
STOCK HOLDERS' EQUITY (Details)	Jul. 05, 2012 USD ($) shares	May 15, 2012 USD ($) shares	Mar. 14, 2012 USD ($) shares	Dec. 12, 2011 USD ($) shares	Aug. 31, 2012 USD ($) $ / shares $ / warrants shares	May 31, 2011 USD ($) shares	Apr. 30, 2011 USD ($) $ / shares shares	Mar. 31, 2011 USD ($) $ / shares $ / warrants shares	Jan. 31, 2011 $ / warrants shares	Nov. 30, 2012 USD ($) $ / shares shares	Nov. 30, 2011 USD ($)	Feb. 28, 2011 USD ($) $ / shares $ / warrants shares	Aug. 31, 2012 USD ($) $ / warrants	Aug. 31, 2011 USD ($) shares	Aug. 31, 2010 USD ($)	Aug. 31, 2009 USD ($)	Aug. 31, 2008 USD ($)	Aug. 31, 2007 USD ($)	Aug. 31, 2012 USD ($) $ / warrants	Nov. 30, 2012 USD ($) shares	Oct. 30, 2012 USD ($) shares	Sep. 30, 2012 $ / warrants shares	Sep. 27, 2012 USD ($)	Aug. 28, 2012 $ / warrants shares	Feb. 15, 2011 $ / warrants shares
Related Party Transaction [Line Items]
Securities Purchase Agreements, number of units							93,701					808,956
Number of shares authorized by warrant									182,292													2,826		246,341
Securities Purchase Agreements, purchase price per unit \| $ / shares							$ 3.84					$ 384.0
Proceeds from issuance of shares \| $							$ 359,800			$ 1,458,436		$ 3,106,000	$ 3,488,942	$ 3,694,212					$ 15,144,635	$ 16,603,071
Securities Purchase Agreements, number of shares per unit							1					1
Securities Purchase Agreements, number of warrants per unit							1					1
Securities Purchase Agreements, number of shares per warrant							0.35					0.35
Warrant term					5 years		5 years		5 years			5 years
Exercise price per share \| $ / warrants					6.0			6.0	6.0			6.0	6.0						6.0					4.44
Stock issued for services, shares								16,397
Stock issued for services \| $													$ 107,860	$ 227,569	$ 249,850	$ 152,928	$ 116,110	$ 98,750
Finders fee \| $					$ 71,250
Service agreement consideration \| $																							$ 3,500,000
D.N.A. Biomedical Solutions Ltd. [Member]
Related Party Transaction [Line Items]
Number of shares to be sold								65,104													199,172
Number of shares authorized by warrant								22,787
Securities Purchase Agreements, purchase price per unit \| $ / shares								$ 3.84
Proceeds from issuance of shares \| $								$ 250,000
Securities Purchase Agreements, number of shares per unit								1
Securities Purchase Agreements, number of warrants per unit								0.35
Exercise price per share \| $ / warrants								6.0
Service agreement consideration \| $																					$ 628,630
Option to purchase shares of D.N.A.																					21,637,611
Percent shares owned by investor																					7.10%
Percentage of D.N.A. shares owned																					14.50%
Number of D.N.A. shares ownded																					8,404,667
Swiss Caps AG [Member]
Related Party Transaction [Line Items]
Stock issued for services, shares						14,744								44,220
Stock issued for services \| $						$ 47,769								$ 167,569
Advisor [Member]
Related Party Transaction [Line Items]
Number of shares authorized by warrant																									62,500
Exercise price per share \| $ / warrants																									6.0
Stock issued for services, shares		6,917	6,917	6,917
Stock issued for services \| $		$ 24,900	$ 26,560	$ 24,900
Advisor Two [Member]
Related Party Transaction [Line Items]
Stock issued for services, shares	4,167		4,167
Stock issued for services \| $	$ 15,500		$ 16,000
Securities Purchase Agreement [Member]
Related Party Transaction [Line Items]
Securities Purchase Agreements, number of units					801,942
Securities Purchase Agreements, purchase price per unit \| $ / shares					$ 4.44
Proceeds from issuance of shares \| $					$ 3,560,192
Securities Purchase Agreements, number of shares per unit					1
Securities Purchase Agreements, number of warrants per unit					1
Securities Purchase Agreements, number of shares per warrant					0.5
Warrant term					5 years
Exercise price per share \| $ / warrants					6.0								6.0						6.0
Securities Purchase Agreement Two [Member]
Related Party Transaction [Line Items]
Securities Purchase Agreements, number of units					5,652
Proceeds from issuance of shares \| $					$ 25,093
Leading Investor [Member]
Related Party Transaction [Line Items]
Securities Purchase Agreements, number of units										405,405
Number of shares to be sold																						5,652
Number of shares authorized by warrant																						2,826
Other Individual [Member]
Related Party Transaction [Line Items]
Number of shares to be sold										1,127										1,127
Number of shares authorized by warrant										564										564
Finders fee \| $										$ 5,835
Additional finders fee \| $										$ 7,500
Directors [Member]
Related Party Transaction [Line Items]
Number of shares to be sold										12,745										12,745
Number of shares authorized by warrant										6,373										6,373
Securities Purchase Agreement [Member]
Related Party Transaction [Line Items]
Securities Purchase Agreements, number of units										329,832
Securities Purchase Agreements, purchase price per unit \| $ / shares										$ 4.44
Proceeds from issuance of shares \| $										$ 1,464,425
Securities Purchase Agreements, number of shares per unit										1
Securities Purchase Agreements, number of warrants per unit										1
Securities Purchase Agreements, number of shares per warrant										0.5
Warrant term										5 years
Exercise price per share \| $ / warrants																						6.0

STOCK BASED COMPENSATION (Narrative) (Details)					1 Months Ended						3 Months Ended		4 Months Ended	12 Months Ended					65 Months Ended	125 Months Ended	128 Months Ended
STOCK BASED COMPENSATION (Narrative) (Details)	Aug. 08, 2012 USD ($) $ / shares $ / warrants shares	Jul. 25, 2011 USD ($) $ / warrants shares	Apr. 27, 2011 USD ($) $ / shares shares	Feb. 15, 2011 USD ($) $ / warrants shares	Aug. 31, 2012 USD ($) $ / warrants shares	Jul. 31, 2011 USD ($)	May 31, 2011 USD ($) shares	Apr. 30, 2011 USD ($) $ / shares shares	Mar. 31, 2011 $ / warrants shares	Jan. 31, 2011 $ / warrants shares	Nov. 30, 2012 USD ($) shares	Nov. 30, 2011 USD ($)	Feb. 28, 2011 USD ($) $ / shares $ / warrants shares	Aug. 31, 2012 USD ($) $ / warrants shares	Aug. 31, 2011 USD ($) shares	Aug. 31, 2010 USD ($)	Aug. 31, 2009 USD ($)	Aug. 31, 2008 USD ($)	Aug. 31, 2007 USD ($)	Aug. 31, 2012 USD ($) $ / warrants shares	Nov. 30, 2012 USD ($) shares	Sep. 30, 2012 shares	Aug. 28, 2012 $ / warrants shares	May 08, 2008 shares	Oct. 15, 2006 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for grant	83,334
Stock issued for services, shares									16,397
Stock issued for services \| $														$ 107,860	$ 227,569	$ 249,850	$ 152,928	$ 116,110	$ 98,750
Options to purchase, number of shares										182,292												2,826	246,341
Options to purchase, exercise price per share \| $ / warrants					6.0				6.0	6.0			6.0	6.0						6.0			4.44
Securities Purchase Agreements, number of units								93,701					808,956
Securities Purchase Agreements, purchase price per unit \| $ / shares								$ 3.84					$ 384.0
Proceeds from issuance of shares \| $								$ 359,800			$ 1,458,436		$ 3,106,000	$ 3,488,942	$ 3,694,212					$ 15,144,635	$ 16,603,071
Securities Purchase Agreements, number of shares per unit								1					1
Securities Purchase Agreements, number of warrants per unit								1					1
Securities Purchase Agreements, number of shares per warrant								0.35					0.35
Warrant term					5 years			5 years		5 years			5 years
Issuance of common stock \| $						$ 43,176
Number of warrants issued		5,622			112,613				5,906	182,292				112,613						112,613
Fair value of options granted \| $						$ 11,050
Expected dividend yield (%)						0.00%			0.00%					0.00%	0.00%
Expected volatility						79.28%
Expected stock price volatility (%), minimum									78.54%					76.03%	112.50%
Expected stock price volatility (%), maximum									78.68%					76.03%	114.20%
Risk-free interest rate						2.09%
Risk-free interest rate (%), minimum									2.11%					0.80%	1.60%
Risk-free interest rate (%), maximum									2.19%					1.00%	3.60%
Remaining contractual life						5			5
Swiss Caps AG [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued for services, shares							14,744								44,220
Stock issued for services \| $							$ 47,769								$ 167,569
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase, number of shares				20,834
Options to purchase, exercise price per share \| $ / warrants				12.0
Options vesting, number of installments				5
Fair value of options granted \| $				$ 62,185										$ 54,345
Expected dividend yield (%)				0.00%										0.00%
Expected volatility				78.65%										75.41%
Risk-free interest rate				3.62%										1.29%
Remaining contractual life				10										8.5
Employee of Subsidiary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted - at market price	609,000
Granted - at market price \| $ / shares	$ 0.34
Options vesting, number of installments	29
Fair value of options granted \| $	$ 170,301
Expected dividend yield (%)	0.00%
Expected volatility	111.22%
Risk-free interest rate	0.935%
Remaining contractual life	10
Nadav Kidron and Miriam Kidron [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted - at market price	144,000
Granted - at market price \| $ / shares	$ 4.08
Options vested	42,000
Number of warrants issued	6,000
Options vesting, number of installments	17
Fair value of options granted \| $	$ 373,565
Expected dividend yield (%)	0.00%
Expected volatility	76.03%
Risk-free interest rate	0.83%
Remaining contractual life	5.5
Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted - at market price	43,334
Granted - at market price \| $ / shares	$ 4.08
Options to purchase, number of shares											6,373										6,373
Options vesting, number of installments	2
Fair value of options granted \| $	$ 114,694
Expected dividend yield (%)	0.00%
Expected volatility	76.03%
Risk-free interest rate	1.0375%
Remaining contractual life	5.75
Subsidiary Employee One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase, number of shares	50,750
Options to purchase, exercise price per share \| $ / warrants	4.08
Number of warrants issued	1,750
Options vesting, number of installments	29
Fair value of options granted \| $	$ 134,324
Expected dividend yield (%)	0.00%
Expected volatility	76.03%
Risk-free interest rate	1.0375%
Remaining contractual life	5.75
Subsidiary Employee Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase, number of shares	6,250
Options to purchase, exercise price per share \| $ / warrants	4.08
Options vesting, number of installments	3
Fair value of options granted \| $	$ 16,780
Expected dividend yield (%)	0.00%
Expected volatility	76.03%
Risk-free interest rate	0.935%
Remaining contractual life	6
Dr. Miriam Kidron [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase, number of shares	280,114
ExperiMind Ltd [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued for services, shares			3,584
Granted - at market price \| $ / shares			$ 6.0
Fair value of options granted \| $			$ 10,000
Expected dividend yield (%)			0.00%
Expected volatility			79.24%
Risk-free interest rate			2.06%
Remaining contractual life			5
New Castle Consulting [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued for services, shares							16,667
Stock issued for services \| $							$ 60,000
Trout Group LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase, number of shares		2,667
Options to purchase, exercise price per share \| $ / warrants		6.5
Options vesting, number of installments		12
Fair value of options granted \| $		$ 5,057			$ 4,548
Expected dividend yield (%)		0.00%			0.00%
Expected volatility		77.39%			75.41%
Risk-free interest rate		1.55%			0.45%
Remaining contractual life		10
2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for grant																									250,000
2008 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for grant	333,334				1,000,000									1,000,000						1,000,000				666,667
2008 Stock Option Plan [Member] \| Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase, number of shares				250,000
Options vesting, number of installments				5
Fair value of options granted \| $				$ 71,495
Expected dividend yield (%)				0.00%
Expected volatility				113.80%
Risk-free interest rate				3.42%

STOCK BASED COMPENSATION (Schedule of Fair Value Assumptions) (Details)	1 Months Ended		12 Months Ended
	Jul. 31, 2011	Mar. 31, 2011	Aug. 31, 2012	Aug. 31, 2011
STOCK BASED COMPENSATION [Abstract]
Expected option life (years), minimum			5	5
Expected option life (years), maximum			6	10
Expected stock price volatility (%), minimum		78.54%	76.03%	112.50%
Expected stock price volatility (%), maximum		78.68%	76.03%	114.20%
Risk-free interest rate (%), minimum		2.11%	0.80%	1.60%
Risk-free interest rate (%), maximum		2.19%	1.00%	3.60%
Expected dividend yield (%)	0.00%	0.00%	0.00%	0.00%

STOCK BASED COMPENSATION (Schedule of Stock Option Activity) (Details) - $ / shares	12 Months Ended
	Aug. 31, 2012	Aug. 31, 2011
Employees [Member]
Number of options
Options outstanding at beginning of year	834,117	834,117
Granted - at market price	244,334
Expired	(141,667)
Forfeited	(4,667)
Options outstanding at end of year	932,116	834,117
Options exercisable at end of year	717,088	743,785
Weighted average fair value of options granted during the year
Weighted average exercise price
Options outstanding at beginning of year	3.84	3.84
Granted - at market price	4.08
Expired	5.4
Forfeited	5.64
Options outstanding at end of year	$ 3.72	$ 3.84
Nonemployees [Member]
Number of options
Options outstanding at beginning of year	82,356	67,767
Granted - at market price
Granted - above market price	62,500	27,089
Expired		(12,500)
Options outstanding at end of year	144,456	82,356
Options exercisable at end of year	88,689	50,521
Weighted average exercise price
Options outstanding at beginning of year	$ 7.2	$ 7.56
Granted - at market price
Granted - above market price	6.0	6.0
Expired		(8.52)
Options outstanding at end of year	$ 6.72	$ 7.2

STOCK BASED COMPENSATION (Summary of Information for Options Outstanding and Exercisable by Exercise Price Range) (Details)	Aug. 31, 2012 USD ($) $ / shares shares
Employees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	932,116
Outstanding, weighted average remaining contractual life, years	6.14
Outstanding, weighted average exercise price \| $ / shares	$ 3.72
Outstanding, aggregate intrinsic value \| $	$ 1,072,274
Number exercisable \| shares	717,088
Exercisable, weighted average remaining contractual life, years	5.07
Exercisable, weighted average exercise price \| $ / shares	$ 3.48
Exercisable, aggregate intrinsic value \| $	$ 1,072,274
Nonemployees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	144,456
Outstanding, weighted average remaining contractual life, years	4.8
Outstanding, weighted average exercise price \| $ / shares	$ 6.72
Outstanding, aggregate intrinsic value \| $
Number exercisable \| shares	88,689
Exercisable, weighted average remaining contractual life, years	4.53
Exercisable, weighted average exercise price \| $ / shares	$ 6.96
Exercisable, aggregate intrinsic value \| $
$0.012 [Member] \| Employees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	280,114
Outstanding, weighted average remaining contractual life, years	1.93
Outstanding, weighted average exercise price \| $ / shares	$ 0.012
Outstanding, aggregate intrinsic value \| $	$ 1,072,274
Number exercisable \| shares	280,114
Exercisable, weighted average remaining contractual life, years	1.93
Exercisable, weighted average exercise price \| $ / shares	$ 0.012
Exercisable, aggregate intrinsic value \| $	$ 1,072,274
$4.08 to 6.48 [Member] \| Employees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	652,002
Outstanding, weighted average remaining contractual life, years	7.95
Outstanding, weighted average exercise price \| $ / shares	$ 5.76
Outstanding, aggregate intrinsic value \| $
Number exercisable \| shares	436,974
Exercisable, weighted average remaining contractual life, years	7.08
Exercisable, weighted average exercise price \| $ / shares	$ 5.28
Exercisable, aggregate intrinsic value \| $
$4.08 to 6.48 [Member] \| Nonemployees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	111,120
Outstanding, weighted average remaining contractual life, years	4.79
Outstanding, weighted average exercise price \| $ / shares	$ 5.88
Outstanding, aggregate intrinsic value \| $
Number exercisable \| shares	58,131
Exercisable, weighted average remaining contractual life, years	4.15
Exercisable, weighted average exercise price \| $ / shares	$ 5.88
Exercisable, aggregate intrinsic value \| $
$9.12 [Member] \| Nonemployees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	33,336
Outstanding, weighted average remaining contractual life, years	4.83
Outstanding, weighted average exercise price \| $ / shares	$ 9.12
Outstanding, aggregate intrinsic value \| $
Number exercisable \| shares	30,558
Exercisable, weighted average remaining contractual life, years	5.25
Exercisable, weighted average exercise price \| $ / shares	$ 9.12
Exercisable, aggregate intrinsic value \| $

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Nov. 30, 2012	Aug. 31, 2012	Aug. 31, 2011
ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]
Service providers		$ 580,714	$ 339,052
Payroll and related expenses		16,459	36,486
Accounts payable and accrued expenses	$ 287,302	$ 597,173	$ 375,538

RESEARCH AND DEVELOPMENT EXPENSES, NET (Details) - USD ($)	3 Months Ended		12 Months Ended		125 Months Ended	128 Months Ended
	Nov. 30, 2012	Nov. 30, 2011	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012	Nov. 30, 2012
RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]
Clinical trials			$ 1,298,310	$ 591,733	$ 5,163,353
Payroll and consulting fees			385,646	413,191	1,921,533
Costs for registration of patents			110,811	189,342	451,610
Compensation costs in respect of options granted to employees, directors and consultants			98,688	265,327	2,921,881
Other			160,350	49,444	547,608
Less - grants from the OCS			(372,959)	(349,728)	(1,468,290)
Research and Development Expense	$ 392,626	$ 184,016	$ 1,680,845	$ 1,159,309	$ 9,532,694	$ 9,925,320

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References + Details

GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)	3 Months Ended		12 Months Ended		125 Months Ended	128 Months Ended
GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)	Nov. 30, 2012	Nov. 30, 2011	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012	Nov. 30, 2012
GENERAL AND ADMINISTRATIVE EXPENSES [Abstract]
Compensation costs in respect of options granted to employees, directors and consultants			$ 172,470	$ 263,999	$ 2,049,406
Professional services			221,218	344,277	1,899,744
Consulting fees			159,136	171,167	970,900
Travel costs			71,529	54,976	545,930
Write off of debt					275,000
Business development			284,899	151,886	815,945
Payroll and related expenses			144,101	174,229	753,208
Insurance			22,375	23,890	118,921
Other			127,436	91,536	732,493
General and Administrative Expense	$ 339,213	$ 281,901	$ 1,203,164	$ 1,275,960	$ 8,161,547	$ 8,500,760

TAXES ON INCOME (Narrative) (Details) - USD ($)	12 Months Ended
TAXES ON INCOME (Narrative) (Details) - USD ($)	Aug. 31, 2012	Aug. 31, 2011
Taxes On Income [Line Items]
Corporate tax rate	35.00%
Net operating loss carryforwards	$ 4,896,605	$ 3,468,280
Penalties related to tax contingencies	$ 15,539	34,105
Subsidiary [Member]
Taxes On Income [Line Items]
Corporate tax rate	25.00%
Net operating loss carryforwards	$ 5,905,361	$ 3,328,946

TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details) - USD ($)	Aug. 31, 2012	Aug. 31, 2011
TAXES ON INCOME [Abstract]
Net operating loss carryforward	$ 3,190,152	$ 1,813,108
Less - Valuation allowance	(3,190,152)	(1,813,108)
Net deferred tax assets

TAXES ON INCOME (Schedule of Income Taxes Included in the Income Statements) (Details) - USD ($)	3 Months Ended		12 Months Ended		125 Months Ended	128 Months Ended
	Nov. 30, 2012	Nov. 30, 2011	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012	Nov. 30, 2012
TAXES ON INCOME [Abstract]
U.S.			$ 599,067	$ 415,836	$ 8,440,543
Outside U.S.			2,655,193	1,169,389	9,210,458
Loss before taxes on income	$ 958,753	$ 478,519	3,254,260	1,585,225	17,651,001	$ 18,609,754
U.S.			(7,569)	(33,567)	62,001
Outside U.S.			97,787	9,587	202,755
Taxes on income			$ 90,218	$ (23,980)	$ 240,776	$ 240,776

TAXES ON INCOME (Schedule of Reconciliation of Income Taxes) (Details) - USD ($)	3 Months Ended		12 Months Ended		125 Months Ended	128 Months Ended
	Nov. 30, 2012	Nov. 30, 2011	Aug. 31, 2012	Aug. 31, 2011	Aug. 31, 2012	Nov. 30, 2012
TAXES ON INCOME [Abstract]
Loss before income taxes as reported in the consolidated statement of operations	$ (958,753)	$ (478,519)	$ (3,254,260)	$ (1,585,225)	$ (17,651,001)	$ (18,609,754)
Statutory tax benefit			(1,138,991)	(554,829)	(6,177,851)
Change in the balance of the valuation allowance for deferred tax losses			516,749	(58,357)	2,762,468
Disallowable deductions			120,156	481,122	2,244,091
Increase in taxes resulting from different tax rates applicable to non U.S. subsidiary			502,086	132,064	1,183,796
Uncertain tax position			90,218	(23,980)	228,272
Taxes on income			$ 90,218	$ (23,980)	$ 240,776	$ 240,776

TAXES ON INCOME (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)	12 Months Ended
	Aug. 31, 2012	Aug. 31, 2011
TAXES ON INCOME [Abstract]
Balance at Beginning of Year	$ 138,054	$ 162,034
Increase (decrease) in tax positions for prior years	90,218	(23,980)
Balance at End of Year	$ 228,272	$ 138,054

RELATED PARTIES - TRANSACTIONS (Narrative) (Details) - USD ($)	12 Months Ended
	Aug. 31, 2012	Aug. 31, 2011
Directors [Member]
Related Party Transaction [Line Items]
Amount of transaction	$ 30,000	$ 30,000
Subsidiary Consulting Agreement [Member]
Related Party Transaction [Line Items]
Written notice requirement	60 days
Monthly fee	$ 12,512
JV Agreement [Member]
Related Party Transaction [Line Items]
Amount of transaction	36,000
Monthly fee	$ 869

RELATED PARTIES - TRANSACTIONS (Schedule of Balances with Related Parties) (Details) - USD ($)	Nov. 30, 2012	Aug. 31, 2012	Aug. 31, 2011
RELATED PARTIES - TRANSACTIONS [Abstract]
Current assets - related parties - Entera	$ 1,719	$ 404
Accounts payable and accrued expenses - KNRY			$ 18,502

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

SUBSEQUENT EVENTS (Details)	1 Months Ended							3 Months Ended		4 Months Ended	12 Months Ended		125 Months Ended	128 Months Ended
SUBSEQUENT EVENTS (Details)	Dec. 20, 2012 USD ($) $ / shares shares	Oct. 30, 2012 USD ($) $ / warrants shares	Aug. 31, 2012 USD ($) $ / warrants shares	Jul. 31, 2011	Apr. 30, 2011 USD ($) $ / shares shares	Mar. 31, 2011 $ / warrants	Jan. 31, 2011 $ / warrants shares	Nov. 30, 2012 USD ($) $ / shares shares	Nov. 30, 2011 USD ($)	Feb. 28, 2011 USD ($) $ / shares $ / warrants shares	Aug. 31, 2012 USD ($) $ / warrants shares	Aug. 31, 2011 USD ($) shares	Aug. 31, 2012 USD ($) $ / warrants shares	Nov. 30, 2012 USD ($) shares	Jan. 10, 2013	Nov. 29, 2012 $ / warrants shares	Sep. 30, 2012 $ / warrants shares	Sep. 27, 2012 USD ($)	Aug. 28, 2012 $ / warrants shares
Subsequent Event [Line Items]
Expected dividend yield (%)				0.00%		0.00%					0.00%	0.00%
Expected volatility				79.28%
Risk-free interest rate				2.09%
Remaining contractual life				5		5
Number of shares authorized by warrant							182,292										2,826		246,341
Securities Purchase Agreements, number of units					93,701					808,956
Proceeds from issuance of shares \| $					$ 359,800			$ 1,458,436		$ 3,106,000	$ 3,488,942	$ 3,694,212	$ 15,144,635	$ 16,603,071
Securities Purchase Agreements, purchase price per unit \| $ / shares					$ 3.84					$ 384.0
Securities Purchase Agreements, number of shares per unit					1					1
Securities Purchase Agreements, number of warrants per unit					1					1
Securities Purchase Agreements, number of shares per warrant					0.35					0.35
Warrant term			5 years		5 years		5 years			5 years
Exercise price per share \| $ / warrants			6.0			6.0	6.0			6.0	6.0		6.0						4.44
Finders fee \| $			$ 71,250
Service agreement consideration \| $																		$ 3,500,000
Reverse stock split ratio															12
Common stock, shares issued, prior to reverse stock split			80,100,000					86,500,000			80,100,000		80,100,000	86,500,000
Common stock, shares outstanding, prior to reverse stock split			80,100,000					86,500,000			80,100,000		80,100,000	86,500,000
Common stock, shares issued			6,673,829					7,209,652			6,673,829	5,842,803	6,673,829	7,209,652			5,652
Common stock, shares outstanding			6,673,829					7,209,652			6,673,829	5,842,803	6,673,829	7,209,652
Common stock, shares authorized, prior to reverse stock split			200,000,000					200,000,000			200,000,000		200,000,000	200,000,000
Common stock, shares authorized			16,666,667					16,666,667			16,666,667	16,666,667	16,666,667	16,666,667
Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Number of shares authorized by warrant		21,637,611															6,373
Securities Purchase Agreements, number of units								329,832
Proceeds from issuance of shares \| $		$ 628,630						$ 1,464,425
Securities Purchase Agreements, purchase price per unit \| $ / shares								$ 4.44
Securities Purchase Agreements, number of shares per unit								1
Securities Purchase Agreements, number of warrants per unit								1
Securities Purchase Agreements, number of shares per warrant								6
Warrant term								5 years
Exercise price per share \| $ / warrants																	0.5
Common stock, shares issued		199,172															12,745
Subsidiary Employee [Member]
Subsequent Event [Line Items]
Options granted	4,667
Exercise price \| $ / shares	$ 6.0
Fair value \| $	$ 9,660
Expected dividend yield (%)	0.00%
Expected volatility	64.35%
Risk-free interest rate	1.01%
Remaining contractual life	5.75
Number of shares per installment	2,334
Leading Investor [Member]
Subsequent Event [Line Items]
Number of shares authorized by warrant		3,485,500														137,311
Securities Purchase Agreements, number of units								405,405
Exercise price per share \| $ / warrants		3.7656														7.2
Other Individual [Member]
Subsequent Event [Line Items]
Number of shares authorized by warrant																	564
Finders fee \| $								$ 5,385
Additional finders fee \| $								$ 7,500
Common stock, shares issued																	1,127
Directors [Member]
Subsequent Event [Line Items]
Options granted	20,000
Exercise price \| $ / shares	$ 6.0
Fair value \| $	$ 41,402
Expected dividend yield (%)	0.00%
Expected volatility	64.35%
Risk-free interest rate	1.01%
Remaining contractual life	5.75